---- CONTRAINDICATIONS -

CONTRAINDICATIONS WARNINGS AND PRECAUTIONS Non-infectious Pneumonitis Severe Hypersensitivity Reactions Angioedema with Concomitant Use of Angiotensin-Converting Enzyme (AČE) Inhibitors Renal Failure Risk of Impaired Wound Healing 5.8 Geriatric Patients FULL PRESCRIBING INFORMATION 1.1 Hormone Receptor-Positive, HER2-Negative Breast Cancer
Everolimus Tablets are indicated for the treatment of postmenopausal women with advanced hormone receptorpositive, HER2-negative breast cancer in combination with exemestane, after failure of treatment with letrozole **Everolimus Tablets** 1.2 Neuroendocrine Tumors (NET)
Everolimus Tablets are indicated for the treatment of adult patients with progressive neuroendocrine tumors of pancreatic origin (PNET) with unresectable, locally advanced or metastatic disease. R03/2022

EVEROLIMUS TABLETS safely and effectively. See full prescribing information ---- RECENT MAJOR CHANGES ------- INDICATIONS AND USAGE --

· Renal failure: Monitor renal function prior to treatment and periodically thereafter. Risk of Impaired Wound Healing: Withhold for at least 1 week prior to elective yound healing complications has not been established. (5.7)

discontinue based on severity. (2.9, 5.2)

hypersensitivity (5.3)

angioedema. (5.4, 7.2)

surgery. Do not administer for at least 2 weeks following major surgery and until adequate wound healing. The safety of resumption of treatment after resolution of · Geriatric Patients: Monitor and adjust dose for adverse reactions. (5.8) Metabolic Disorders: Monitor serum glucose and lipids prior to treatment and periodically thereafter. Withhold or permanently discontinue based on severity (2.9, 5.9)

Severe Hypersensitivity Reactions: Permanently discontinue for clinically significant

Angioedema: Patients taking concomitant angiotensin-converting-enzyme (ACE)

inhibitors may be at increased risk for angioedema. Permanently discontinue for

Stomatitis: Initiate dexamethasone alcohol-free mouthwash when starting treat-

2.12 Dosage Modifications for P-gp and CYP3A4 Inducers

• Avoid concomitant use of St. John's Wort (Hypericum perfo Avoid concomitant use of St. John's Wort (Hypericum pertoratum).
 Increase the dose for patients taking Everolimus Tablets with a P-gp and strong CYP3A4 inducer as recommended in Table 5 [see Drug Interactions (7.1), Clinical Pharmacology (12.3)]. Myelosuppression: Monitor hematologic parameters prior to treatment and periodi cally thereafter. Withhold or permanently discontinue based on severity. (2.9, 5.10) Risk of Infection or Reduced Immune Response with Vaccination: Avoid live vac. cines and close contact with those who have received live vaccines. Complete recommended childhood vaccinations prior to starting treatment. (5.11) Radiation Sensitization and Radiation Recall: Severe radiation reactions may and TSC-Associated Renal

occur. (5.12, 6.2) Embryo-Fetal Toxicity: Can cause fetal harm. Advise patients of reproductive pote tial of the potential risk to a fetus and to use effective contraception. (5.13, 8.1, 8.3)

• Breast cancer, PNET, RCC: Most common adverse reactions (incidence ≥30%) include stomatitis, infections, rash, fatigue, diarrhea, edema, abdominal pain, nausea, fever, asthenia, cough, headache and decreased appetite. (6.1) TSC-Associated Renal Angiomyolipoma: Most common adverse reaction (incidence ≥ 30%) is stomatitis. (6.1) • TSC-Associated SEGA: Most common adverse reactions (incidence ≥ 30%) are

-- ADVERSE REACTIONS -

stomatitis and respiratory tract infection. (6.1) To report SUSPECTED ADVERSE REACTIONS, contact Par Pharmaceutical at 1-800-828-9393 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. ---- DRUG INTERACTIONS

• P-qp and strong CYP3A4 inhibitors: Avoid concomitant use. (2.11, 7.1) P-gp and moderate CYP3A4 inhibitors: Reduce the dose as recommended. (2.11,

• P-gp and strong CYP3A4 inducers: Increase the dose as recommended. (2.12, 7.1) --- USE IN SPECIFIC POPULATIONS --

• For breast cancer, PNET, RCC, or TSC-associated renal angiomyolipoma patients with hepatic impairment, reduce the dose, (2.10, 8.6) For patients with TSC-associated SEGA and severe hepatic impairment, reduce the starting dose and adjust dose to attain target trough concentrations. (2.8, 2.10, 8.6) See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient

5.9 Metabolic Disorders

5.10 Myelosuppression
5.11 Risk of Infection or Reduced Immune Response with Vaccination 5.12 Radiation Sensitization and Radiation Recall 5 13 Embryo-Fetal Toxicity

ADVERSE REACTIONS Clinical Trials Experience

DRUG INTERACTIONS Effect of Other Drugs on Everolimus Tablets

7.2 Effects of Combination Use of Angiotensin Converting Enzyme (ACE) USE IN SPECIFIC POPULATIONS

Lactation Females and Males of Reproductive Potential Pediatric Use

Geriatric Use Hepatic Impairmen DESCRIPTION CLINICAL PHARMACOLOGY

Mechanism of Action 2 Pharmacodynamics 12.3 Pharmacokinetics NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility13.2 Animal Toxicology and/or Pharmacology **CLINICAL STUDIES**

14.1 Hormone Receptor-Positive, HER2-Negative Breast Cancer 14.2 Neuroendocrine Tumors (NET)

14.3 Renal Cell Carcinoma (RCC)

 14.4 Tuberous Sclerosis Complex (TSC)-Associated Renal Angiomyolipoma
 14.5 Tuberous Sclerosis Complex (TSC)-Associated Subependymal Giant Cell Astrocytoma (SEGA) REFERENCES

vious dose; change to every other day dosing if the reduced dose is

If recurs at Grade 2, withhold until improvement to Grade 0 or 1

Resume at 50% of previous dose; change to every other day dosing if the reduced dose is lower than the lowest available strength.

Withhold until improvement to Grade 0 or 1. Resume at 50% of pre-

vious dose; change to every other day dosing if the reduced dose is ower than the lowest available strength.

Withhold until improvement to Grade 0, 1 or 2. Resume at 50% of

previous dose; change to every other day dosing if the reduced

If toxicity becomes intolerable, withhold until improvement to Gra

If toxicity recurs at Grade 2, withhold until improvement to Grade

0 or 1. Resume at 50% of previous dose; change to every other day dosing if the reduced dose is lower than the lowest available

at 50% of previous dose; change to every other day dosing if the reduced dose is lower than the lowest available strength

Withhold until improvement to Grade 0 or 1. Resume at same do

Grade 3 Withhold until improvement to Grade 0, 1 or 2. Resume at same

Grade 4 Withhold until improvement to Grade 0, 1 or 2. Resume at 50% of

Withhold until improvement to Grade 0 or 1. Resume at 50% of pre-

vious dose; change to every other day dosing if the reduced dose is

previous dose; change to every other day dosing if the reduced dose is lower than the lowest available strength.

Withhold until improvement to Grade 0, 1 or 2 and no fever. Resume at 50% of previous dose; change to every other day dosing if the reduced dose is lower than the lowest available strength.

Dose Modification for Everolimus Tablets

Grade 3 Withhold until improvement to Grade 0 or 1. Consider resu

If recurs at Grade 3, permanently discontinue.

ower than the lowest available strength

ower than the lowest available strength

is lower than the lowest available strength.

Permanently discontinue

0 or 1. Resume at same dose.

Permanently discontinue.

Grade 4 Permanently discontinue

The recommended dosages of Everolimus Tablets for patients with hepatic impairment are described in Table 3

Table 3: Recommended Dosage Modifications for Patients with Hepatic Impairment

Grade 4 Permanently discontinue.

If toxicity recurs at Grade 3, permanently discontinue.

Grade 2 Withhold until improvement to Grade 0 or 1. Resume at same dose.

HOW SUPPLIED/STORAGE AND HANDLING PATIENT COUNSELING INFORMATION Sections or subsections omitted from the full prescribing information are not listed

Adverse Reaction Severity Dosage Modification

Isee Warnings and

Precautions (5.5)]

(e.g., hyperglycemia

Precautions (5.9)]

Isee Warnings and

[see Warnings and

Isee Warnings and

2.10 Dosage Modifications for Hepatic Impairment

[see Use in Specific Populations (8.6)]:

Indication

cautions (5.1)]

Table 2: Recommended Dosage Modifications for Everolimus Tablets for Adverse Reactions atitis, including mouth ulcers and oral mucositis, has occurred in patients treated with Everolimus Tablets Stomatitis, including mouth ulcers and oral mucositis, has occurred in patients treated with Everolinus Tables at an incidence ranging from 44% to 78% across the clinical trials. Grades 3-4 stomatitis was reported in 4% to 3% of patients (see Adverse Reactions (6.1)). Stomatitis most often occurs within the first 8 weeks of treatment. When starting Everolimus Tablets, initiating dexamethasone alcohol-free oral solution as a swish and spir mouth-wash reduces the incidence and severity of stomatitis (see Adverse Reactions (6.1)). If stomatitis does occur, mouthwashes and/or other topical treatments are recommended. Avoid alcohol-, hydrogen peroxide-, iodine-, or thyme- containing products, as they may exacerbate the condition. Do not administer antifungal agents, unless fungal infection has been diagnosed. Withhold until improvement to Grade 0 or 1. Resume at 50% of previous dose; change to every other day dosing if the reduced dose is lower than the lowest available strength. Permanently discontinue if toxicity does not resolve or improve Withhold until improvement to Grade 0 or 1. Resume at 50% of pre

5.6 Renal Failure
Cases of renal failure (including acute renal failure), some with a fatal outcome, have occurred in patients taking
Everollimus Tablets. Elevations of serum creatinine and proteinuria have been reported in patients taking
Everollimus Tablets (see Adverse Reactions (6.1)). The incidence of Grade 3 and 4 elevations of serum creatinine
was up to 2% and up to 1%, respectively. The incidence of Grade 3 and 4 proteinuria was up to 1% and to
0.5%, respectively. Monitor renal function prior to starting Everollimus Tablets and annually thereafter. Monitor
renal function at least every 6 months in patients who have additional risk factors for renal failure.

Table 4: Recommended Dosage Modifications for Concurrent Use of Everolimus Tablets with

Dose Modification for Everolimus Tablets

Resume the dose administered prior to inhibitor initiation, once the

Change to every other day dosing if the reduced dose is lower than the

· Resume dose administered prior to inhibitor initiation, once the inhibitor

Assess trough concentrations when initiating and discontinuing the inhibitor [see Dosage and Administration (2.8)].

· Avoid coadministration where alternatives exist.

an inducer is discontinued for 5 days.

increments may be required

3 Administration and Preparation
Administer Everolimus Tablets at the same time each day.
Administer Everolimus Tablets consistently either with or without food [see Clinical Pharmacology (12.3)].
If a dose of Everolimus Tablets is missed, it can be administered up to 6 hours after the time it is normally administered. After more than 6 hours, the dose should be skipped for that day. The next day, Everolimus Tablets should be administered at its usual time. Double doses should not be administered to make up for the dose that was missed.

White to slightly yellow, capsule shaped tablets with a beveled edge and no score, engraved with "P" on one side and "119" on the other side.

White to slightly yellow, capsule shaped tablets with a beveled edge and no score, engraved with "P" on one side and "125" on the other side.

White to slightly yellow, capsule shaped tablets with a beveled edge and no score, engraved with "P" on one

White to slightly yellow, capsule shaped tablets with a beveled edge and no score, engraved with "P" on one side and "128" on the other side.

Everolimus Tablets are contraindicated in patients with clinically significant hypersensitivity to everolimus or to other rapamycin derivatives (see Warnings and Precautions (5.3)).

5.1 Non-infectious Pneumonitis
Non-infectious pneumonitis is a class effect of rapamycin derivatives. Non-infectious pneumonitis was reported in up to 19% of patients treated with Everolimus Tablets in clinical trials, some cases were reported with pulmonary hypertension (including pulmonary arterial hypertension) as a secondary event. The incidence of Grade 3 and 4 non-infectious pneumonitis was up to 4% and up to 0.2%, respectively [see Adverse Reactions (6.1)]. Fatal outcomes have been observed.

Continue Everolimus Tablets without dose alteration in patients who develop radiological changes suggestive of non-infectious pneumonitis and have few or no symptoms. Imaging appears to overestimate the incidence

For Grade 2 to 4 non-infectious pneumonitis, withhold or permanently discontinue Everolimus Tablets based on severity (see Dosage and Administration (2.9)). Corticosteroids may be indicated until clinical symptoms resolve. Administer prophylaxis for PJP when concomitant use of corticosteroids or other immunosuppressive agents are required. The development of pneumonitis has been reported even at a reduced dose.

5.2 Infections

Everolimus Tablets has immunosuppressive properties and may predispose patients to bacterial, fungal, viral, or protozoal infections, including infections with opportunistic pathogens [see Adverse Reactions (6.1)]. Localized and systemic infections, including pneumonia, mycobacterial infections, other bacterial infections in vinasive fungal infections (e.g., aspergillosis, candidiasis, or PJP) and viral infections (e.g., reactivation of hepatitis B virus) have

occurred. Some of these infections have been severe (e.g., sepsis, septic shock, or resulting in multisystem organ failure) or fatal. The incidence of Grade 3 and 4 infections was up to 10% and up to 3%, respectively. The incidence of serious infections was reported at a higher frequency in patients < 6 years of age [see Use in Specific Populations (8.4)].

Complete treatment of preexisting invasive fungal infections prior to starting treatment. Monitor for signs and symptoms of infection. Withhold or permanently discontinue Everolimus Tablets based on severity of infection

Administer prophylaxis for PJP when concomitant use of corticosteroids or other immunosuppressive agents

5.3 Severe Hypersensitivity Reactions
Hypersensitivity reactions to Everolimus Tablets have been observed and include anaphylaxis, dyspnea, flushing, chest pain, and angloedema (e.g., swelling of the airways or fortigue, with or without respiratory impairment) [see Contraindications (4)]. The incidence of Grade 3 hypersensitivity reactions was up to 1%. Permanently discontinue Everolimus Tablets for the development of clinically significant hypersensitivity.

5.4 Angioedema with Concomitant Use of Angiotensin-Converting Enzyme (ACE) Inhibitors
Patients taking concomitant ACE inhibitors with Everolimus Tablets may be at increased risk for angioedema
(e.g., swelling of the airways or tongue, with or without respiratory impairment). In a pooled analysis of randomized double-blind oncology clinical trials, the incidence of anjoedema in patients taking everolimus with
an ACE inhibitor was 6.8% compared to 1.3% in the control arm with an ACE inhibitor. Permanently discontinue
Everolimus Tablets for angioedema.

Consider a diagnosis of non-infectious pneumonitis in patients presenting with non-specific resp symptoms. Consider opportunistic infections such as pneumocystis jiroveci pneumonia (PJP) diagnosis. Advise patients to report promptly any new or worsening respiratory symptoms.

<u>Everolimus Tablets</u>
• Everolimus Tablets should be swallowed whole with a glass of water. Do not break or crush tablets.

Dose Modification for Everolimus Tablets

using increments of 5 mg or less. Multiple increments may be

· Resume the dose administered prior to inducer initiation, once

• Double the daily dose using increments of 5 mg or less. Multiple

Addition of another strong CYP3A4 inducer in a patient already

receiving treatment with a strong CYP3A4 inducer may not

Assess trough concentrations when initiating and discontinuing the inducer [see Dosage and Administration (2.8)]

• Resume the dose administered before starting any inducer, once

a P-gp and Moderate CYP3A4 Inhibito

Reduce dose to 2.5 mg once daily.

inhibitor is discontinued for 3 days.

Table 5: Recommended Dosage Modifications for Concurrent Use of Everolimus Tablets with P-gp

and Strong CYP3A4 Inducers

Reduce the daily dose by 50%

lowest available strength.

SC-Associated SEGA

SC-Associated SEGA

3 DOSAGE FORMS AND STRENGTHS

4 CONTRAINDICATIONS

5 WARNINGS AND PRECAUTIONS

[see Dosage and Administration (2.9)].

• May increase dose to 5 mg once daily if tolerated

5.7 Risk of Impaired Wound Healing fore, Everolimus Tablets have the potential to adversely affect wound healing. Withhold Everolimus Tablets for at least 1 week prior to elective surgery. Do not administer for at least 2 weeks following major surgery and until adequate wound healing. The safety of resumption of treatment upon resolution of wound healing complications has not been established.

5.8 Geriatric Patients 5.8 Geriatric Patients
In the randomized hormone receptor-positive, HER2-negative breast cancer study (BOLERO-2), the incidence of deaths due to any cause within 28 days of the last Everolimus tablets dose was 6% in patients ≥ 65 years of age compared to 2% in patients < 65 years of age. Adverse reactions leading to permanent treatment idecontinuation occurred in 33% of patients > 65 years of age compared to 17% in patients < 65 years of age. Careful monitoring and appropriate dose adjustments for adverse reactions are recommended [see Dosage and Administration (2.9).</p>

5.9 Metabolic Disorders

5.10 Myelosuppression
Anemia, lymphopenia, neutropenia, and thrombocytopenia have been reported in patients taking Everolimus
Tablets. The incidence of these Grade 3 and 4 laboratory abnormalities was up to 16% and up to 2%, respectively
[see Adverse Reactions (6.1)]. Monitor complete blood count (CBC) prior to starting Everolimus Tablets every
6 months for the first year of treatment and annually thereafter. Withhold or permanently discontinue Everolimus
Tablets based on severity [see Dosage and Administration (2.9)].

5.11 Risk of Infection or Reduced Immune Response with Vaccination

The safety of immunization with live vaccines during Everolimus Tablets therapy has not been studied. Due to the potential increased risk of infection, avoid the use of live vaccines and close contact with individuals who have received live vaccines during treatment with Everolimus Tablets. Due to the potential increased risk of infection or reduced immune response with vaccination, complete the recommended childhood series of vaccinations according to American Council on Immunization Practices (ACIP) guidelines prior to the start of therapy. An accelerated vaccination schedule may be appropriate.

5.12 Radiation Sensitization and Radiation Recall Radiation sensitization and recall, in some cases severe, involving cutaneous and visceral organs (including radiation esophagitis and pneumonitis) have been reported in patients treated with radiation prior to, during or subsequent to Everolimus Tablets treatment [see Adverse Reactions (6.2)]. Monitor patients closely when Everolimus Tablets is administered during or sequentially with radiation treatment

5.13 Embryo-Fetal Toxicity
Based on animal studies and the mechanism of action Everolimus Tablets can cause fetal harm when adminis Based on animal studies and the mechanism of action Everolimus Tablets can cause fetal harm when adminis-tered to a pregnant woman. In animal studies, everolimus caused embryo-fetal toxicities in rats when adminis-tered during the period of organogenesis at maternal exposures that were lower than human exposures at the clinical dose of 10 mg once daily. Advise pregnant women of the potential risk to a fetus. Advise female patients of reproductive potential to avoid becoming pregnant and to use effective contraception during treatment with Everolimus Tablets and for 8 weeks after the last dose. Advise male patients with female partners of reproductive potential to use effective contraception during treatment with Everolimus Tablets and for 4 weeks after the last dose [see Use in Specific Populations (8.1, 8.3)].

Impaired Wound Healing [see Warnings and Precautions (5.7)]
Metabolic Disorders [see Warnings and Precautions (5.9)]. Myelosuppression [see Warnings and Precautions (5.10)].
Radiation Sensitization and Radiation Recall [see Warnings and Precautions (5.12)]. 6.1 Clinical Trials Experience be directly compared to rates in other trials and may not reflect the rates observed in clinical practice

The most common adverse reactions (incidence ≥ 30%) were stomatitis, infections, rash, fatigue, diarrhea, and

hypokalemia, increased AST, increased ALT, and thrombocytopenia.

Fatal adverse reactions occurred in 2% of patients who received Everolimus. The rate of adverse reactions resulting in permanent discontinuation was 24% for the Everolimus arm. Dose adjustments (interruptions or reductions) occurred in 63% of patients in the Everolimus arm.

Adverse reactions reported with an incidence of \geq 10% for patients receiving Everolimus versus placebo are presented in Table 6. Laboratory abnormalities are presented in Table 7. The median duration of treatment with Everolimus was 23.9 weeks; 33% were exposed to Everolimus for a period of \geq 32 weeks.

	with Exe	Everolimus Tablets with Exemestane N=482		cebo mestane 238
	All grades	Grade 3-4 %	All grades	Grade 3-4 %
Gastrointestinal				
Stomatitis®	67	8 ^d	11	0.8
Diarrhea	33	2	18	0.8
Nausea	29	0.4	28	1
Vomiting	17	1	12	0.8
Constipation	14	0.4 ^d	13	0.4
Dry mouth	11	0	7	0
General				
Fatigue	36	4	27	1 ^d
Edema peripheral	19	1 ^d	6	0.4 ^d
Pyrexia	15	0.2 ^d	7	0.4 ^d
Asthenia	13	2	4	0
Infections				
Infections ^b	50	6	25	2 ^d
Investigations	'			
Weight loss	25	1 ^d	6	0
Metabolism and nutrition	•	•		
Decreased appetite	30	1 ^d	12	0.4 ^d
Hyperglycemia	14	5	2	0.4 ^d
Musculoskeletal and conne	ctive tissue			
Arthralgia	20	0.8 ^d	17	0
Back pain	14	0.2 ^d	10	0.8 ^d
Pain in extremity	9	0.4 ^d	11	2 ^d
Nervous system				
Dysgeusia	22	0.2 ^d	6	0
Headache	21	0.4 ^d	14	0
Psychiatric				
Insomnia	13	0.2 d	8	0
Respiratory, thoracic and m	ediastinal			
Cough	24	0.6 d	12	0
Dyspnea	21	4	11	1
Epistaxis	17	0	1	0
Pneumonitis ^c	19	4	0.4	0
Skin and subcutaneous tiss	ue			
Rash	39	1 ^d	6	0
Pruritus	13	0.2 ^d	5	0
A1	40	_	_	0

Grading according to NCI CTCAE Version 3.0 cludes stomatitis, mouth ulceration, aphthous stomatitis, glossodynia, gingival pain, glossitis udes all reported infections including, but not limited to, urinary tract infections, respiratory tract (upper and lower) infections, skin infections, and gastrointestinal tract infections.

Includes pneumonitis, interstitial lung disease, lung infiltration, and pulmonary fibrosis.

No Grade 4 adverse reactions were reported.

Hot flush

6 0 14 0

Table 7: Selected Laboratory Abnormalities Reported in ≥ 10% of Patients with

Hormor	ne Receptor-Positiv	ve Breast Cancer	in BOLERO-2	
Laboratory parameter	with Exe	us Tablets mestane 482	with Exe	cebo mestane 238
	All grades	Grade 3-4	All grades	Grade 3-4
	%	%	%	%
Hematology				
Anemia	68	6	40	1
Leukopenia	58	2 ^b	28	6
Thrombocytopenia	54	3	5	0.4
Lymphopenia	54	12	37	6
Neutropenia	31	2 ^b	11	2
Chemistry	•			
Hypercholesterolemia	70	1	38	2
Hyperglycemia	69	9	44	1
Increased AST	69	4	45	3
Increased ALT	51	4	29	5 ^b
Hypertriglyceridemia	50	0.8b	26	0
Hypoalbuminemia	33	0.8 ^b	16	0.8 ^b
Hypokalemia	29	4	7	1 ^b
Increased Creatinine	24	2	13	0
Grading according to NCI C	TCAE Version 3.0			

rading according to Not C ICAE Version 3.0
Reflects corresponding adverse drug reaction reports of anemia, leukopenia, lymphopenia, neutropenia, and thrombocytopenia (collectively as pancytopenia), which occurred at lower frequency.
No Grade 4 laboratory abnormalities were reported.

Topical Prophylaxis for Stomattis

In a single arm study (SWISH; N = 92) in postmenopausal women with hormone receptor-positive, HER2-negative breast cancer beginning Everolimus Tablets (10 mg orally once daily) in combination with exemestane (25 mg orally once daily), patients started dexamethasone 0.5 mg/5mL alcohol-free mouthwash (10 mL swished for 2 minutes and spat, 4 times daily for 8 weeks) concurrently with Everolimus Tablets and exemestane. No food or drink was to be consumed for at least 1 hour after swishing and spitting the dexamethasone mouthwash. The primary objective of this study was to assess the incidence of Grade 2 to 4 stomatitis within 8 weeks was 2%, which was lower than the 33% reported in the BOLERO-2 trial. The incidence of Grade 1 stomatitis was 19%. No cases of Grade 3 or 4 stomatitis were reported. Oral candidiasis was reported in 2% of patients in this study compared to 0.2% in the BOLERO-2 trial.

Pancreatic Neuroendocrine Tumors (PNET)
In a randomized, controlled trial (RADIANT-3) of Everolimus Tablets (n = 204) vs. placebo (n = 203) in patients with advanced PNET the median age of patients was 58 years (20 to 87 years), 79% were White, and 55% were male. Patients on the placebo arm could cross over to open-label Everolimus Tablets upon disease progression. The most common adverse reactions (incidence ≥ 30%) were stomatitis, rash, diarrhea, fatigue, edema, abdominal pain, nausea, fever, and headache. The most common Grade 3-4 adverse reactions (incidence ≥ 5%) were stomatitis and diarrhea. The most common laboratory abnormalities (incidence ≥ 50%) were anemia, hyperglycemia, increased alkaline phosphatase, hypercholesterolemia, decreased bicarbonate, and increased AST. The most common Grade 3-4 laboratory abnormalities (incidence ≥ 3%) were hyperglycemia, lymphopenia, anemia, hypophosphatemia, increased alkaline phosphatase, neutropenia, increased AST, hypokalemia, and thrombo-

Deaths during double-blind treatment where an adverse reaction was the primary cause occurred in seven patients on Everolimus Tablets. Causes of death on the Everolimus Tablets arm included one case of each of the following: acute renal failure, acute respiratory distress, cardiac arrest, death (cause unknown), hepatic failure, payments and sense. After cores over to poor label. Everolimus Tablets: there were three additional deaths. pneumonia, and sepsis. After cross-over to open-label Everolimus Tablets, there were three additional deaths, one due to hypoglycemia and cardiac arrest in a patient with insulinoma, one due to myocardial infarction with congestive heart failure, and the other due to sudden death. The rate of adverse reactions resulting in permanent discontinuation was 20% for the Everolimus Tablets group. Dose delay or reduction was necessary in 61% of Everolimus Tablets patients. Grade 3.4 renal failure occurred in six patients in the Everolimus Tablets arm. Thrombotic events included five patients with pulmonary embolus in the Everolimus Tablets arm as well as three patients with thrombosis in the Everolimus Tablets arm.

Table 8 compares the incidence of adverse reactions reported with an incidence of ≥ 10% for patients receiving Everolimus Tablets vs. placebo. Laboratory abnormalities are summarized in **Table 9**. The median duration of treatment in patients who received Everolimus Tablets was 37 weeks. In female patients aged 18 to 55 years, irregular menstruation occurred in 5 of 46 (11%) Everolimus Tablets

Table 8: Adverse Reactions Reported in ≥10% of Patients with PNET in RADIANT-3

Everolimus Tablets N = 204 Placebo N = 203 All Grades Grade 3-4 All Grades Grade 3-4 % % Muscle spasms Nervous System Dysgeusia Dyspnea/dyspnea exertiona uritus/pruritus generalized

ng according to NCI CTCAE Version 3.0 Grading according to NO CICAE version 3.0

Includes stomatifis, aphthous stomatifis, gingival pain/swelling/ulceration, glossitis, glossodynia, lipulceration, mouth ulceration, tongue ulceration, and mucosal inflammation.

Includes diarrhea, enteritis, enterocolitis, colitis, defecation urgency, and steatorrhea.

Includes pneumonitis, interstitial lung disease, pulmonary fibrosis, and restrictive pulmonary disease. Table 9: Selected Laboratory Abnormalities Reported in ≥ 10% of Patients with PNET in RADIANT-3

Everolimus Tablets

	IN-	N=204 N=203		203
	All grades	Grade 3-4	All grades	Grade 3-4
	%	%	%	%
Hematology				
Anemia	86	15	63	1
Lymphopenia	45	16	22	4
Thrombocytopenia	45	3	11	0
Leukopenia	43	2	13	0
Neutropenia	30	4	17	2
Chemistry				
Hyperglycemia (fasting)	75	17	53	6
Increased alkaline phosphatase	74	8	66	8
Hypercholesterolemia	66	0.5	22	0
Bicarbonate decreased	56	0	40	0
Increased AST	56	4	41	4
Increased ALT	48	2	35	2
Hypophosphatemia	40	10	14	3
Hypertriglyceridemia	39	0	10	0
Hypocalcemia	37	0.5	12	0
Hypokalemia	23	4	5	0
Increased creatinine	19	2	14	0
Hyponatremia	16	1	16	1
Hypoalbuminemia	13	1	8	0
Hyperbilirubinemia	10	1	14	2
Hyperkalemia	7	0	10	0.5

Renal Cell Carcinoma (RCC)
The data described below reflect exposure to Everolimus Tablets (n = 274) and placebo (n = 137) in a randomized, controlled trial (RECORD-1) in patients with metastatic RCC who received prior treatment with sunitinib zeo, componed una (neconder) in patients with metastatic KCC who received prior treatment with sunfinite and/or sorafenib. The median age of patients was 61 years (27 to 85 years), 88% were White, and 8% were nale. The median duration of blinded study treatment was 141 days (19 to 451 days) for patients receiving

The most common adverse reactions (incidence \geq 30%) were stomatitis, infections, asthenia, fatigue, cough, and diarrhea. The most common Grade 3-4 adverse reactions (incidence \geq 3%) were infections, dyspnea, fatigue, stomatitis, dehydration, pneumonitis, abdominal pain, and asthenia. The most common laboratory abnormalities (incidence \geq 50%) were anemia, hypercholesterolemia, hypertriglyceridemia, hyperglycemia, lymphopenia, and increased creatinine. The most common Grade 3-4 laboratory abnormalities (incidence \geq 3%) were lymphopenia, hyperglycemia, anemia, hypophosphatemia, and hypercholesterolemia. Deaths due to acute respiratory failure (0.7%), infection (0.7%), and acute renal failure (0.4%) were observed of

Deaths due to acute respiratory lainte (cr. ns), interaction or any, and acute retain latinate (cr. ns), more conserved the Everolimus Tablets arm. The rate of adverse reactions resulting in permanent discontinuation was 14% for the Everolimus Tablets group. The most common adverse reactions leading to treatment discontinuation were pneumonitis and dyspone. Infections, stomatitis, and pneumonitis were the most common reasons for treatment delay or dose reduction. The most common medical interventions required during Everolimus Tablets treatment were for infections, anemia, and stomatitis Adverse reactions reported with an incidence of ≥ 10% for patients receiving Everolimus Tablets versus placebo are presented in Table 12. Laboratory abnormalities are presented in Table 13.

Table 12: Adverse Reactions Reported in ≥ 10% of Patients with RCC and at a Higher Rate in Grade 3-4 All Grades % Mucosal inflammation Respiratory, thoracic and mediastinal Metabolism and nutrition **Nervous System** lusculoskeletal and connective tissue
Pain in extremity 10

Grading according to NCI CTCAE Version 3.0

* Stomatitis (including aphthous stomatitis), and mouth and tongue ulceration.

* Includes all reported infections including, but not limited to, respiratory tract (upper and lower) infections, urinary tract infections, and skin infections.

c Includes pneumonitis, interstitial lung disease, lung infiltration, pulmonary, alveolar hemorrhage pulmonary toxicity, and alveolitis. No Grade 4 adverse reactions were reported. Other notable adverse reactions occurring more frequently with Everolimus Tablets than with placebo, but with

an incidence of < 10% include: Firmclude of < 10 % include:
Eastrointestinal: Abdominal pain (9%), dry mouth (8%), hemorrhoids (5%), dysphagia (4%) General: Weight loss (%), chest pain (5%), chills (4%), impaired wound healing (< 1%) Respiratory, thoracic and mediastinal: Pleural effusion (7%), pharyngolaryngeal pain (4%), rhinorrhea (3%)

Skin and subcutaneous tissue: Hand-foot syndrome (reported as palmar-plantar erythrodysesthesia syndrome) (5%), nail disorder (5%), erythema (4%), onychoclasis (4%), skin lesion (4%), acneiform dermatitis (3%), Metabolism and nutrition: Exacerbation of pre-existing diabetes mellitus (2%), new onset of diabetes mellitus

Psychiatric: Insomnia (9% Nervous system: Dizziness (7%), paresthesia (5%) Ocular: Eyelid edema (4%), conjunctivitis (2%) Vascular: Hypertension (4%), deep vein thrombosis (< 1%) Renal and urinary: Renal failure (3%) Hematologic: Hemorrhage (3%)

the Everolimus Arm Than the Placebo Arm in RECORD-Placebo N = 137 All Grades Grade 3-4 All Grades Grade 3-4 % Hematology Lymphopenia 23 1^b 2 <1 <1b Hyperglycemia 25 1 7 0 21 1^b 4 0 Increased ALT Hyperbilirubinemia

Grading according to NCI CTCAE Version 3.0 Reflects corresponding adverse drug reaction reports of anemia, leukopenia, lymphopenia, neutropenia, and thrombocytopenia (collectively pancytopenia), which occurred at lower frequency

Tuberous Sclerosis Complex (TSC)-Associated Renal Angiomyolipoma

The data described below are based on a randomized (2:1), double-blind, placebo-controlled trial (EXIST-2) of Everolimus Tablets in 118 patients with renal angiomyolipoma as a feature of TSC (n = 113) or sporadic lymphangioleiomyomatosis (n = 5). The median age of patients was 31 years (18 to 61 years), 89% were White, and 34% were male. The median duration of blinded study treatment was 48 weeks (2 to 115 weeks) for patients receiving Everolimus Tablets. The most common adverse reaction reported for Everolimus Tablets (incidence ≥ 30%) was stomatitis. The most

The most common daverse reaction incidence ≥ 2%) were stomatitis and amenormae. The most common laboratory abnormalities (incidence ≥ 5%) were stomatitis and amenormae. The most common laboratory abnormalities (incidence ≥ 50%) were hypercholesterolemia, hypertriglyceridemia, and anemia. The most common Grade 3-4 laboratory abnormality (incidence ≥ 3%) was hypophosphatemia.

The rate of adverse reactions resulting in permanent discontinuation was 3.8% in the Everolimus-treated patients. Adverse reactions leading to permanent discontinuation in the Everolimus Tablets arm were hypersensitivity/ angioedema/bronchospasm, convulsion, and hypophosphatemia. Dose adjustments (interruptions or reductions) due to adverse reactions occurred in 52% of Everolimus-treated patients. The most common adverse reaction leading to Everolimus Tablets dose adjustment was stomatitis.

Adverse reactions reported with an incidence of ≥ 10% for patients receiving Everolimus Tablets and occurring

	eported in ≥ 10% ed Renal Angiom	yolipoma in EX	(IST-2	
	Everolimus Tablets N = 79		Placebo N = 39	
	All Grades %	Grade 3-4 %	All Grades	Grade 3-4 %
Gastrointestinal				
Stomatitis ^a	78	6 ^b	23	0
Vomiting	15	0	5	0
Diarrhea	14	0	5	0
General				
Peripheral edema	13	0	8	0
Infections				
Upper respiratory tract infection	11	0	5	0
Musculoskeletal and connective ti	ssue			
Arthralgia	13	0	5	0
Respiratory, thoracic and mediast	inal			
Cough	20	0	13	0
Skin and subcutaneous tissue				
Acne	22	0	5	0

PATIENT INFORMATION Everolimus (E ver OH li mus) Tablets

Read this Patient Information leaflet that comes with Everolimus Tablets before

you start taking it and each time you get a refill. There may be new information. This information does not take the place of talking to your healthcare provider about your medical condition or treatment. What is the most important information I should know about Everolimus

1. You may develop lung or breathing problems. In some people lung or

breathing problems may be severe and can lead to death. Tell your health-

You may be more likely to develop an infection, such as pneumonia, or a

bacterial, fungal or viral infection. Viral infections may include active hepatitis

Everolimus Tablets can cause serious side effects, including:

care provider right away if you have any of these symptoms:

New or worsening cough

Difficulty breathing or wheezing

Shortness of breath

Chest pain

B in people who have had hepatitis B in the past (reactivation). In some people (including adults and children) these infections may be severe and can lead to death. You may need to be treated as soon as possible. Tell your healthcare provider right away if you have a temperature of 100.5°F or above, chills, or do not feel well.

Symptoms of hepatitis B or infection may include the following: Chills Skin rash Joint pain and swelling

 Tiredness Loss of appetite Nausea Pale stools or dark urine Yellowing of the skin
 Pain in the upper right side of the stomach

Severe allergic reactions. Call your healthcare provider or get medical help right away if you get signs and symptoms of a severe allergic reaction including: rash, itching, hives, flushing, trouble breathing or swallowing, chest pain or dizziness.

Possible increased risk for a type of allergic reaction called angioedema, in people who take an Angiotensin-Converting Enzyme (ACE) inhibitor medicine during treatment with Everolimus Tablets. Talk with your healthcare provider before taking Everolimus Tablets if you are not sure if you take an ACE inhibitor medicine. Get medical help right away if you have trouble breathing or develop swelling of your tongue, mouth, or throat during treatment with Everolimus Tablets.

Mouth ulcers and sores. Mouth ulcers and sores are common during treatment with Everolimus Tablets but can also be severe. When you start treatment with Everolimus Tablets, your healthcare provider may tell you to also start a prescription mouthwash to reduce the likelihood of getting mouth ulcers or sores and to reduce their severity. Follow your healthcare provider's instructions on how to use this prescription mouthwash. If you develop pain, discomfort, or open sores in your mouth, tell your healthcare provider. Your healthcare provider may tell you to restart this mouthwash or to use a special mouthwash or mouth gel that does not contain alcohol, peroxide, iodine or

You may develop kidney failure. In some people this may be severe and can lead to death. Your healthcare provider should do tests to check your kidney function before and during your treatment with Everolimus

If you have any of the serious side effects listed above, you may need to stop taking Everolimus Tablets for a while or use a lower dose. Follow your healthcare provider's instructions.

What are Everolimus Tablets?

Everolimus Tablets are a prescription medicine used to treat: advanced hormone receptor-positive, HER2-negative breast cancer, along with the medicine exemestane, in postmenopausal women who have

already received certain other medicines for their cancer adults with a type of pancreatic cancer known as pancreatic neuroendocrine tumor (PNET), that has progressed and cannot be treated with surgery.

Everolimus Tablets are not for use in people with carcinoid tumors that actively produce hormones · adults with advanced kidney cancer (renal cell carcinoma or RCC) when

certain other medicines have not worked. people with the following types of tumors that are seen with a genetic condition called tuberous sclerosis complex (TSC):

o adults with a kidney tumor called angiomyolipoma, when their kidney tumor does not require surgery right away. adults and children 1 year of age and older with a brain tumor called subependymal giant cell astrocytoma (SEGA) when the tumor cannot

is not known if Everolimus Tablets are safe and effective in children to treat: hormone receptor-positive, HER2-negative breast cancer kidney cancer (renal cell carcinoma)

• a kidney tumor called angiomyolipoma, that can happen in children with a genetic condition called tuberous sclerosis complex (TSC).

Do not take Everolimus Tablets if you have had a severe allergic reaction to everolimus. Talk to your healthcare provider before taking this medicine if you are allergic to

 a medicine that contains sirolimus a medicine that contains temsirolimus Ask your healthcare provider if you do not know.

be removed completely by surgery

Before taking Everolimus Tablets, tell your healthcare provider about all of vour medical conditions, including if you: Have or have had kidney problems

Have or have had liver problems Have diabetes or high blood sugar

 Have high blood cholesterol levels Have any infections

 Previously had hepatitis B Are scheduled to receive any vaccinations. You should not receive a "live vaccine" or be around people who have recently received a "live vaccine" during your treatment with Everolimus Tablets. If you are not sure about the type of immunization or vaccine, ask your healthcare provider. For children with TSC and SEGA or certain types of seizures, work with your healthcare provider to complete the recommended childhood series of vaccines before your child starts treatment with Everolimus Tablets.

 Are pregnant, can become pregnant, or have a partner who can become pregnant. Everolimus Tablets can cause harm to your unborn baby. Females who are able to become pregnant:

 Your healthcare provider will give you a pregnancy test before you start treatment with Everolimus Tablets.

You should use effective birth control during treatment and for 8 weeks after your last dose of Everolimus tablets.

Males with a female partner, you should use effective birth control during treatment and for 4 weeks after your last dose of Everolimus Tablets.

Talk to your healthcare provider about birth control methods that may be right for you during this time. If you become pregnant or think you are pregnant, tell

your healthcare provider right away. · Are breastfeeding or plan to breastfeed. It is not known if Everolimus Tablets pass into your breast milk. Do not breastfeed during treatment and for I

2 weeks after your last dose of Everolimus tablets. Are planning to have surgery, or if you have had a recent surgery. You should stop taking Everolimus Tablets at least 1 week before planned surgery. See

"What are the possible side effects of Everolimus Tablets?" Have received radiation therapy or are planning to receive radiation therapy in the future. See "What are the possible side effects of Everolimus Tab-

Tell your healthcare provider about all of the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Everolimus Tablets may affect the way other medicines work, and other medicines can affect how Everolimus Tablets work. Taking Everolimus Tablets with

Know the medicines you take. Keep a list of them and show it to your healthcare provider and pharmacist when you get a new medicine. Especially tell your healthcare provider if you take:

I other medicines can cause serious side effects.

itiation or discontinuation of P-gp and moderate CYP3A4 inhibitor nitiation or discontinuation of P-gp and strong 2 weeks CYP3A4 inducer Change in hepatic functio Stable dose with changing body surface area (BSA Every 3 to 6 months Every 6 to 12 months Stable dose with stable BSA Abbreviation: P-gp, P-glycoproteir 2.9 Dosage Modifications for Adverse Reactions Table 2 summarizes recommendations for dosage modifications of Everolimus Tablets for the management of

1.5 Tuberous Sclerosis Complex (TSC)-Associated Subependymal Giant Cell Astrocytoma (SEGA)

2.1 Important Dosage Information
Everolimus Tablets are available in one dosage form: tablets (Everolimus Tablets)

- Modify the dosage for patients with hepatic impairment or for patients taking drugs that inhibit or induce P-glycoprotein (P-gp) and CYP3A4 (see Dosage and Administration (2.10, 2.11, 2.12)).

2.3 Recommended Dosage for Neuroendocrine Tumors (NET)
The recommended dosage of Everolimus Tablets is 10 mg orally once daily until disease progression or unac-

2.5 Recommended Dosage for Tuberous Sclerosis Complex (TSC)-Associated Renal Angiomyolipoma The recommended dosage of Everolimus Tablets is 10 mg orally once daily until disease progression or un

2.6 Recommended Dosage for Tuberous Sclerosis Complex (TSC)-Associated Subependymal Giant Cell

Astrocytonia (SEGA). The recommended starting dosage of Everolimus Tablets is 4.5 mg/m² orally once daily until disease progression or unacceptable toxicity [see Dosage and Administration (2.8)].

2.8 Therapeutic Drug Monitoring (TDM) and Dose Titration for Tuberous Sclerosis Complex (TSC)-Asso-

Agust the dose using the following equation:

New dose" = current dose x (target concentration divided by current concentration)

*The maximum dose increment at any titration must not exceed 5 mg. Multiple dose titrations may be required

Table 1: Recommended Timing of Therapeutic Drug Monitoring

ciated Subependymal Giant Cell Astrocytoma (SEGA)

Monitor everolimus whole blood trough concentrations at time points recommended in Table 1.

- Titrate the dose to attain trough concentrations of 5 ng/mL to 15 ng/mL.

When possible, use the same assay and laboratory for TDM throughout treatment

limus Tablets is 10 mg orally once daily until disease progression or unac

When to Assess Trough Concentrations

1 to 2 weeks

1 to 2 weeks

2.2 Recommended Dosage for Hormone Receptor-Positive, HER2-Negative Breast Cancer The recommended dosage of Everolimus Tablets is 10 mg orally once daily until disease progressions and the control of t

2.4 Recommended Dosage for Renal Cell Carcinoma (RCC)

Adjust the dose using the following equation:

to attain the target trough concentration.

nitiation of Everolimus Tablets

Indification of Everolimus Tablets dose

Event

Everolimus Tablets are indicated in adult and pediatric patients aged 1 year and older with TSC for the treatr of SEGA that requires therapeutic intervention but cannot be curatively resected.

2 DOSAGE AND ADMINISTRATION

ceptable toxicity.

Breast Cancer, PNET, RCC, and TSC-Associated Renal dily, decrease the dose to 5 mg orally once daily if a dose of 7.5 mg once daily is not tolerated. Moderate hepatic impairment (Child-Pugh class B) – 5 mg orally once daily; decrease the dose to 2.5 mg orally once daily if a dose of 5 mg once daily is not tolerated. Severe hepatic impairment (Child-Pugh class C) - 2.5 mg orally once daily if the desired benefit outweighs the risk; do not exceed a dose of 2.5 mg once daily. Severe hepatic impairment (Child-Pugh class C) – 2.5 mg/m² orally Adjust dose based on everolimus trough concentrations as recommended [see Dosage and Administration (2.8)]

2.11 Dosage Modifications for P-gp and CYP3A4 Inhibitors

Avoid the concomitant use of P-gp and strong CYP3A4 inhibitors [see Drug Interactions (7.1)] Avoid injesting grapefruit and grapefruit time.

Reduce the dose for patients taking Everolimus Tablets with a P-gp and moderate CYP3A4 inhibitor as recommended in Table 4 [see Drug Interactions (7.1), Clinical Pharmacology (12.3)].

bbreviations: PNET: Pancreatic Neuroendrocrine Tumors; RCC: Renal Cell Carcinoma; SEGA:

Subenendymal Giant Cell Astrocytoma: TSC: Tuberous Sclerosis Comple

The most common adverse reactions (incidence ≥ 30%) were stomatitis, infections, rash, tatigue, diarrihea, and decreased appetite. The most common Grade 3-4 adverse reactions (incidence ≥ 25%) were stomatitis, infections, hyperglycemia, fatigue, dyspnea, pneumonitis, and diarrhea. The most common laboratory abnormalities (incidence ≥ 50%) were hypercholesterollemia, hyperglycemia, increased aspartate transaminase (AST), anemia, lexopenia, thrombocytopenia, hyperplograi, increased alanine transaminase (ALT), and hypertriglyceridemia. The most common Grade 3-4 laboratory abnormalities (incidence ≥ 3%) were lymphopenia, hyperglycemia, anemia,

6 ADVERSE REACTIONS he following serious adverse reactions are described elsewhere in the labeling:

Non-infectious Pneumonitis [see Warnings and Precautions (5.1)].

Infections [see Warnings and Precautions (5.2)].

Severe Hypersensitivity Reactions [see Warnings and Precautions (5.3)].

Angioedema with Concomitant Use of ACE inhibitors [see Warnings and Precautions (5.4)]. Stomatitis [see Warnings and Precautions (5.5)]. Renal failure [see Warnings and Precautions (5.6)]. cause clinical trials are conducted under widely varying conditions, the adverse reaction rates observed cannot Hormone Receptor-Positive, HER2-Negative Breast Cancer

The safety of Everolimus tablets (10 mg orally once daily) in combination with exemestane (25 mg orally once daily) in (n=485) versus placebo in combination with exemestane (n=239) was evaluated in a randomized, controlled trial (BOLERO-2) in patients with advanced or metastatic hormone receptor-positive, HER2-negative breast cancer. The median age of patients was 61 years (range 28 to 93 years), and 75% were White. The median follow-up was approximately 13 months.

Bacterial infections

 Fungal infections Tuberculosis

 Heart conditions or high blood pressure HIV-AIDS Medicines that weaken your immune system (your body's ability to fight infections and other problems)

Ask your healthcare provider or pharmacist if you are not sure if your medicine is one of those taken for the conditions listed above. If you are taking any medicines for the conditions listed above, your healthcare provider might need to prescribe a different medicine or your dose of Everolimus Tablets may need to be changed. You should also tell your healthcare provider before you start taking any new medicine.

How should I take Everolimus Tablets?

 Your healthcare provider will prescribe the dose of Everolimus Tablets that is right for you.

Take Everolimus Tablets exactly as your healthcare provider tells you to. Your healthcare provider may change your dose of Everolimus Tablets or tell

you to temporarily interrupt dosing, if needed. Use scissors to open the blister pack.

Take Everolimus Tablets 1 time each day at about the same time. Take Everolimus Tablets the same way each time, either with food or without

· If you take too much Everolimus Tablets contact your healthcare provider or go to the nearest hospital emergency room right away. Take the pack of

Everolimus Tablets with you. If you miss a dose of Everolimus Tablets, you may still take it if it is less than **6 hours** after the time you normally take it. If it is **more than 6 hours** after you normally take your Everolimus Tablets, skip the dose for that day. The next day, take Everolimus Tablets at your usual time. Do not take 2 doses to make up for a missed dose. If you are not sure about what to do, call your healthcare

You should have blood tests before you start Everolimus Tablets and as needed during your treatment. These will include tests to check your blood cell count, kidney and liver function, cholesterol, and blood sugar levels.

If you take Everolimus Tablets to treat SEGA, you will also need to have blood tests regularly to measure how much medicine is in your blood. This will help your healthcare provider decide how much Everolimus Tablets you need to

Everolimus Tablets:

Swallow Everolimus Tablets whole with a glass of water. Do not take any tablet that is broken or crushed.

What should I avoid while taking Everolimus Tablets? You should not drink grapefruit juice or eat grapefruit during your treatment with

Everolimus Tablets. It may make the amount of Everolimus Tablets in your blood increase to a harmful level. What are the possible side effects of Everolimus Tablets?

Everolimus Tablets can cause serious side effects, including See "What is the most important information I should know about Everolimus Tablets?" for more information.

Risk of wound healing problems. Wounds may not heal properly during Everolimus Tablets treatment. Tell your healthcare provider if you plan to have any surgery before starting or during treatment with Everolimus Tablets. You should stop taking Everolimus Tablets at least 1 week before planned

o Your healthcare provider should tell you when you may start taking

Everolimus Tablets again after surgery. Increased blood sugar and fat (cholesterol and triglyceride) levels in the

blood. Your healthcare provider should do blood tests to check your fasting blood sugar, cholesterol, and triglyceride levels in the blood before you start | and during treatment with Everolimus Tablets. Decreased blood cell counts. Everolimus Tablets can cause you to have

decreased red blood cells, white blood cells, and platelets. Your healthcare provider should do blood tests to check your blood cell counts before you start and during treatment with Everolimus Tablets. Worsening side effects from radiation treatment, that can sometimes be

severe. Tell your healthcare provider if you have had or are planning to receive

The most common side effects of Everolimus Tablets in people with advanced hormone receptor-positive, HER2-negative breast cancer, advanced neuroendocrine tumors of the pancreas, stomach and intestine (gastrointestinal) or lung, and advanced kidney cancer include:

• Stomach-area (abdominal) pain Infections Rash Nausea Feeling weak or tired Fever Diarrhea Cough

 Swelling of arms, hands, feet, ankles, face or other parts of the body Decreased appetite

The most common side effects of Everolimus Tablets in people who have SEGA, renal angiomyolipoma, or certain types of seizures with TSC include respiratory tract infections.

Other side effects that may occur with Everolimus Tablets: · Absence of menstrual periods (menstruation). You may miss 1 or more men-

strual periods. Tell your healthcare provider if this happens. Everolimus tablets may affect fertility in females and may affect your ability to become pregnant. Talk to your healthcare provider if this is a concern for you. Everolimus tablets may affect fertility in males and may affect your ability to

father a child. Talk to your healthcare provider if this is a concern for you. Tell your healthcare provider if you have any side effect that bothers you or does

These are not all the possible side effects of Everolimus Tablets. For more information, ask your healthcare provider or pharmacist.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

How should I store Everolimus Tablets? • Store Everolimus Tablets at room temperature, between 68°F to 77°F (20°C

 Keep Everolimus Tablets in the pack it comes in. Open the blister pack just before taking Everolimus Tablets. Keep Everolimus Tablets dry and away from light.

Do not use Everolimus Tablets that is out of date or no longer needed.

Keep Everolimus Tablets and all medicines out of the reach of children. General information about the safe and effective use of Everolimus Tablets Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use Everolimus Tablets for a condition for which it was not prescribed. Do not give Everolimus Tablets to other people,

even if they have the same problem you have. It may harm them. This leaflet summarizes the most important information about Everolimus Tablets. If you would like more information, talk with your healthcare provider. You can ask your healthcare provider or pharmacist for information written for health-

For more information call **1-800-828-9393** or go to **www.parpharm.com**.

What are the ingredients in Everolimus Tablets?

Active ingredient: everolimus.

R03/2022

Inactive ingredients: hypromellose, butylated hydroxytoluene, lactose anhydrous, crospovidone, colloidal silicon dioxide and magnesium stearate. This Patient Information has been approved by the U.S. Food and Drug Admin-

> Manufactured by: Par Pharmaceutical Chestnut Ridge, NY 10977

Amenorrhea occurred in 15% of Everolimus-treated females (8 of 52). Other adverse reactions involving the

The following additional adverse reactions occurred in less than 10% of Everolimus-treated patients: epistaxis (9%), decreased appetite (6%), otilis media (6%), depression (5%), abnormal taste (5%), increased blood luteinizing hormone (LH) levels (4%), increased blood follied stimulating hormone (FSH) levels (3%), hypersensitivity (3%), ovarian cyst (3%), pneumonitis (1%), and angioedema (1%).

Table 15: Selected Laboratory Abnormalities Reported in Everolimus-Treated Patients with TSC-Associated Renal Angiomyolipoma in EXIST-2

	•			
	Everolimus Tablets N = 79		Placebo N = 39	
	All Grades %	Grade 3-4 %	All Grades %	Grade 3-4 %
Hematology				
Anemia	61	0	49	0
Leukopenia	37	0	21	0
Neutropenia	25	1	26	0
Lymphopenia	20	1ª	8	0
Thrombocytopenia	19	0	3	0
Chemistry				
Hypercholesterolemia	85	1ª	46	0
Hypertriglyceridemia	52	0	10	0
Hypophosphatemia	49	5ª	15	0
Increased alkaline phosphatase	32	1ª	10	0
Increased AST	23	1ª	8	0
Increased ALT	20	1ª	15	0
Hyperglycemia (fasting)	14	0	8	0

Grading according to NCI CTCAE Version 3.0 No Grade 4 laboratory abnormalities were reported

odated safety information from 112 patients treated with Everolimus Tablets for a median duration of 3.9 years entified the following additional adverse reactions and selected laboratory abnormalities: increased partial romboplastin time (63%), increased prothrombin time (40%), decreased fibrinogen (38%), urinary tract infec-in (31%), proteinuria (18%), abdominal pain (16%), pruritus (12%), gastroententis (12%), myalgia (11%), and eumonia (10%).

TSC-Associated Subependymal Giant Cell Astrocytoma (SEGA)
The data described below are based on a randomized (2:1), double-blind, placebo-controlled trial (EXIST-1) of Everolliums Tablets in 117 patients with SEGA and TSC. The median age of patients was 9.5 years (0.8 to 26 years), 93% were White, and 57% were male. The median duration of blinded study treatment was 52 weeks (24

to 89 weeks) for patients receiving Everolimus Tablets. The most common adverse reactions reported for Everolimus Tablets (incidence \geq 30%) were stomatitis and respiratory tract infection. The most common Grade 3-4 adverse reactions (incidence \geq 2%) were stomatitis, pyrexia, pneumonia, gastroenteritis, aggression, agitation, and amenorrhea. The most common laboratory abnormalities (incidence \geq 50%) were hypercholesterolemia and elevated partial thromboplastin time. The most common Grade 3-4 laboratory abnormality (incidence \geq 3%) was neutropenia.

There were no adverse reactions resulting in permanent discontinuation. Dose adjustments (interruptions or reductions) due to adverse reactions occurred in 55% of Everolimus-treated patients. The most common adverse reaction leading to Everolimus Tablets dose adjustment was stomatitis.

Adverse reactions reported with an incidence of ≥ 10% for patients receiving Everolimus Tablets and occurring more frequently with Everolimus Tablets than with placebo are reported in **Table 16**. Laboratory abnormalities are presented in **Table 17**.

Table 46: Advance Boostions Bounded in > 400/ of Figure limits Tracked Botionto with

Table 16: Adverse Reaction			nus-Treated Pati	ents with
T;	SC-Associated S	EGA in EXIST-1		
		ıs Tablets		ebo
	N =	: 78	N =	: 39
	All Grades	Grade 3-4	All Grades	Grade 3-4
	%	%	%	%
Gastrointestinal				
Stomatitis ^a	62	9f	26	3 ^f
Vomiting	22	1 ^f	13	0
Diarrhea	17	0	5	0
Constipation	10	0	3	0
Infections			*	`
Respiratory tract infection ^b	31	3	23	0
Gastroenteritis ^c	10	5	3	0
Pharyngitis streptococcal	10	0	3	0
General				
Pyrexia	23	6 ^f	18	3 ^f
Fatigue	14	0	3	0
Psychiatric				
Anxiety, aggression or other	21	5 ^f	3	0
behavioral disturbanced				
Skin and subcutaneous tissue				
Rashe	21	0	8	0
Acne	10	0	5	0

rading according to NCI CTCAE Version 3.0 udes mouth ulceration, stomatitis, and lip ulceration udes respiratory tract infection, upper respiratory tract infection, and respiratory tract infection viral udes gastroenteritis, gastroenteritis viral, and qastrointestinal infection udes agitation, anxiety, panic attack, aggression, abnormal behavior, and obsessive compulsive

s rash, rash generalized, rash macular, rash maculo-papular, rash papular, dermatitis allergic, No Grade 4 adverse reactions were reported.

nenorrhea occurred in 17% of Everolimus-treated females aged 10 to 55 years (3 of 18). For this same group

The following additional adverse reactions occurred in less than 10% of Everolimus-treated patients: nausea (8%), pain in extremity (8%), insomnia (6%), pneumonia (6%), epistaxis (5%), hypersensitivity (3%), increased blood luteinizing hormone (LH) levels (1%), and pneumonitis (1%).

	Everolimus Tablets N = 78		Placebo N = 39	
	All Grades	Grade 3-4 %	All Grades	Grade 3-4
Hematology				
Elevated partial thromboplastin time	72	3ª	44	5ª
Neutropenia	46	9ª	41	3ª
Anemia	41	0	21	0
Chemistry		•		
Hypercholesterolemia	81	0	39	0
Elevated AST	33	0	0	0
Hypertriglyceridemia	27	0	15	0
Elevated ALT	18	0	3	0
Hypophosphatemia	9	1ª	3	0

^aNo Grade 4 laboratory abnormalities were reported Updated safety information from 111 patients treated with Everolimus Tablets for a median duration of 47 months. identified the following additional notable adverse reactions and selected laboratory abnormalities: decreased ap petite (14%), hyperglycemia (13%), hypertension (11%), urinary tract infection (9%), decreased fibrinogen (8%) cellulitis (6%), abdominal pain (5%), decreased weight (5%), elevated creatinine (5%), and azoospermia (1%).

these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate frequency or establish a causal relationship to drug exposure:

• Blood and lymphatic disorders: Thrombotic microangiopathy

• Cardiac: cardiac failure with some cases reported with pulmonary hypertension (including pulmonary arterial hypertension) as a secondary event

Gastrointestinal: Acute pancreatitis

Nervous System: Reflex sympathetic dystrophy
 Vascular: Arterial thrombotic events, lymphedema
 Siconing and procedural complications: Radiation Sensitization and Radiation Recall

7 DRUG INTERACTIONS

7.1 Effect of Other Drugs on Everolimus Tablets

Inhibitors
Avoid the concomitant use of P-gp and strong CYP3A4 inhibitors [see Dosage and Administration (2.11), Clinical Pharmacology (12.3)]. Reduce the dose for patients taking Everolimus Tablets with a P-gp and moderate CYP3A4 inhibitor as recommended [see Dosage and Administration (2.11), Clinical Pharmacology (12.3)].

Inducers
Increase the dose for patients taking Everolimus Tablets with a P-gp and strong CYP3A4 inducer as recommend-

7.2 Effects of Combination Use of Angiotensin Converting Enzyme (ACE) Inhibitors
Patients taking concomitant ACE inhibitors with Everolimus Tablets may be at increased risk for angioedema.
Avoid the concomitant use of ACE inhibitors with Everolimus Tablets [see Warnings and Precautions (5.4)].

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy
Risk Summary
Based on animal studies and the mechanism of action [see Clinical Pharmacology (12.1)]. Everolimus tablets
can cause fetal harm when administered to a pregnant woman. There are limited case reports of Everolimus
tablets use in pregnant women; however, these reports are not sufficient to inform about risks of birth defects or
miscarriage. In animal studies, everolimus caused embryo-fetal toxicities in rats when administered during the
period of organogenesis at maternal exposures that were lower than human exposures at the recommended dose
of Everolimus Tablets 10 mg orally once daily (see Data). Advise pregnant women of the potential risk to the fetus.

In the U.S. general population, the estimated background risk of major birth defects and miscarriage is 2% to 4% and 15% to 20% of clinically recognized pregnancies, respectively. Animal Data
In animal reproductive studies, oral administration of everolimus to female rats before mating and through organinanimal reproductive studies, oral administration of everolimus to female rats before mating and through organinanimal part of the productive studies, oral administration of everolimus to female rats before mating and through organinanimal part of the productive studies, oral administration of everolimus to female rats before mating and through organinanimal part of the productive studies, oral administration of everolimus to female rats before mating and through organinanimal reproductive studies, oral administration of everolimus to female rats before mating and through organinanimal part of the productive studies, oral administration of everolimus to female rats before mating and through organinanimal part of the productive studies, oral administration of everolimus to female rats before mating and through organinanimal part of the productive studies, oral administration of everolimus to female rats before mating and through organinanimal part of the productive studies and the productive studies are productive studies. n animal reproductive studies, oral administration of everolimus to female rats before mating and through organ-genesis induced embryo-fetal toxicities, including increased resorption, pre-implantation and post-implantation oss, decreased numbers of live fetuses, malformation (e.g., sternal cleft), and retarded skeletal development. These effects occurred in the absence of maternal toxicities. Embryo-fetal toxicities in rats occurred at dosee 0.1 mg/kg (0.6 mg/m²) with resulting exposures of approximately 4% of the human exposure at the recom-nended dose of Everolimus Tablets 10 mg orally once daily based on area under the curve (AUC). In rab-oitis, embryo-toxicity evident as an increase in resorptions occurred at an oral dose of 0.8 mg/kg (9.6 mg/m²), approximately 1.6 times the recommended dose of Everolimus tablets 10 mg orally once daily or the median dose administered to patients with tuberous sclerosis complex (TSC)-associated subependymal giant cell astrocytoma SEGA). The effect in rabbits occurred in the presence of maternal toxicities.

SEGA). The effect in rabbits occurred in the presence of maternal toxicities. In a pre- and post-natal development study in rats, animals were dosed from implantation through lactation. At the dose of 0.1 mg/kg (0.6 mg/m²), there were no adverse effects on delivery and lactation or signs of maternal toxicity, however, there were reductions in body weight (up to 9% reduction from the control) and in survival of offspring (~5% died or missing). There were no drug-related effects on the developmental parameters (morphological development, motor activity, learning, or fertility assessment) in the offspring.

OS119-01-1-03

Risk Summary
There are no data on the presence of everolimus or its metabolites in human milk, the effects of everolimus on The breastfed infant or on milk production. Everolimus and its metabolites passed into the milk of lactating rats at a concentration 3.5 times higher than in maternal serum. Because of the potential for serious adverse reactions in breastfed infants from everolimus, advise women not to breastfed during treatment with Everolimus Tablets

8.3 Females and Males of Reproductive Potential

Contraception
Everolimus Tablets can cause fetal harm when administered to pregnant women [see Use in Specific Populations

Females: Advise female patients of reproductive potential to use effective contraception during treatment with Everolimus tablets and for 8 weeks after the last dose. Males: Advise male patients with female partners of reproductive potential to use effective contraception during

Infertility
Females: Menstrual irregularities, secondary amenorrhea, and increases in luteinizing hormone (LH) and follicle stimulating hormone (FSH) occurred in female patients taking Everolimus tablets. Based on these findings,
Everolimus Tablets, may impair fertility in female patients (see Adverse Reactions (6.1) and Nonclinical Toxicology

Males: Cases of reversible azoospermia have been reported in male patients taking Everolimus. In male rats, sperm motility, sperm count, plasma testosterone levels and fertility were diminished at AUC similar to those of the clinical dose of Everolimus 10 mg orally once daily. Based on these findings, Everolimus Tablets may impair fertility in male patients [see Nonclinical Toxicology (13.1)].

older with TSC-associated SEGA that requires therapeutic intervention but cannot be curatively resected. Use of Everolimus tablets for this indication is supported by evidence from a randomized, double-blind, placebo-controlled trial in adult and pediatric patients (EXIST-1); an open-label, single-arm trial in adult and pediatric etients (Study 2485); and additional pharmacokinetic data in pediatric patients (see Adverse Reactions (6.1), Clinical Pharmacology (12.3), Clinical Studies (14.5)]. The safety and effectiveness of Everolimus tablets have not been established in pediatric patients less than 1 year of age with TSC-associated SEGA

In EXIST-1, the incidence of infections and serious infections were reported at a higher frequency in patients <6 years of age. Ninety-six percent of 23 Everolimus-treated patients <6 years had at least one infection compared to 67% of 55 Everolimus-treated patients ≥6 years. Thirty-five percent of 23 Everolimus-treated patients <6 years of age had at least 1 serious infection compared to 7% of 55 Everolimus-treated patients ≥ 6 years. Although a conclusive determination cannot be made due to the limited number of patients and lack of a comparator arm in the open label follow-up periods of EXIST-1 and Study 2485, Everolimus Tablets did not appear to adversely impact growth and pubertal development in the 115 pediatric patients treated with Everolimus Tablets for a median duration of 4.1 years.

Other Indications
The safety and effectiveness of Everolimus Tablets in pediatric patients have not been established in:

• Hormone receptor-positive, HER2-negative breast cancer

• Neuroendocrine tumors (NET)

• Renal cell carcinoma (RCC)

• TSC-associated renal angiomyolipoma

In BOLERO-2, 40% of patients with breast cancer treated with Everolimus Tablets were ≥ 65 years of age, while 15% were ≥ 75 years of age. No overall differences in effectiveness were observed between elderly and younger patients. The incidence of deaths due to any cause within 28 days of the last Everolimus Tablets dose was 6% in patients ≥ 65 years of age compared to 2% in patients < 65 years of age. Adverse reactions leading to ment discontinuation occurred in 33% of patients ≥ 65 years of age compared to 17% in patients

In RECORD-1, 41% of patients with renal cell carcinoma treated with Everolimus were \geq 65 years of age, while 7% were \geq 75 years of age. In RADIANT-3, 30% of patients with PNET treated with Everolimus were \geq 65 years of age, while 7% were \geq 75 years of age. No overall differences in safety or effectiveness were observed between elderly and younger patients.

Everolimus Tablets exposure may increase in patients with hepatic impairment [see Clinical Pharmacology

For patients with breast cancer, PNET, RCC, and TSC-associated renal angiomyolipoma who have hepatic impairment, reduce the Everolimus dose as recommended [see Dosage and Administration (2.10)]. For patients with TSC-associated SEGA who have severe hepatic impairment (Child-Pugh class C), reduce the starting dose of Everolimus Tablets as recommended and adjust the dose based on everolimus trough concentrations [see Dosage and Administration (2.8, 2.10)].

The chemical name of everolimus is (1R.9S.12S.15R.16E.18R.19R.21R.23S.24E.26E.28E.30S.32S.35R)-1.18dihydroxy-12-[(1R)-2-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycy(oblexyl)-1-methyethyl)-19,30-dimethoxy 15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-aza-tricyclo[30.3.1.0¹³]hexatriaconta-16,24,26,28-tetraene-2,3,

The molecular formula is C₅₃H₆₃NO₁₄ and the molecular weight is 958.2 g/mol. The structural formula is:

Everolimus Tablets for oral administration contain 2.5 mg, 5 mg, 7.5 mg and 10 mg of everolimus and the following inactive ingredients: hypromellose, butylated hydroxytoluene, lactose anhydrous, crospovidone, colloidal silicon dioxide and magnesium stearate. 12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

Everolimus is an inhibitor of mammalian target of rapamycin (mTOR), a serine-threonine kinase, downstream of the Pl3K/AKT pathway. The mTOR pathway is dysregulated in several human cancers and in tuberous sclerosis complex (TSC). Everolimus binds to an intracellular protein, FKBP-12, resulting in an inhibitory complex formation with mTOR complex 1 (mTORC1) and thus inhibition of mTOR kinase activity. Everolimus reduced the activity of S6 ribosomal protein kinase (S6K1) and eukaryotic initiation factor 4E-binding protein (4E-BP1), downstream effectors of mTOR, involved in protein synthesis. S6K1 is a substrate of mTORC1 and phosphorylates the activation domain 1 of the estrogen receptor which results in ligand-independent activation of the receptor. In addition, everolimus inhibited the expression of hypoxia-inducible factor (e.g., HIF-1) and reduced the expression of vascular endothelial growth factor (VEGF). Inhibition of mTOR by everolimus has been shown to reduce cell proliferation, angiogenesis, and glucose uptake in in vitro and/or in vivo studies.

Constitutive activation of the PI3K/Akt/mTOR pathway can contribute to endocrine resistance in breast cancer. In vitro studies show that estrogen-dependent and HER2+ breast cancer cells are sensitive to the inhibitory effects of everolimus, and that combination treatment with everolimus and Akt, HER2, or aromatase inhibitors enhances the anti-tumor activity of everolimus in a synergistic manner. Two regulators of mTORC1 signaling are the oncogene suppressors tuberin-sclerosis complexes 1 and 2 (TSC1, TSC2). Loss or inactivation of either TSC1 or TSC2 leads to activation of downstream signaling. In TSC, a genetic disorder, inactivating mutations in either the TSC1 or the TSC2 gene lead to harmatoma formation throughout the obdy as well as seizures and epileptogenesis. Overactivation of mTOR results in neuronal dysplasia, aberrant axonogenesis and dendrite formation, increased excitatory synaptic currents, reduced myelination, and disruption of the cortical laminar structure causing abnormalities in neuronal development and function. Treatment with an mTOR inhibitor in animal models of mTOR dysregulation in the brain resulted in seizure suppression, prevention of the development of new-onset seizures, and prevention of premature death.

12.2 Pharmacodynamics Exposure-Response Relationship In patients with TSC-associated subependymal giant cell astrocytoma (SEGA), the magnitude of the reduction in SEGA volume was correlated with the everolimus trough concentration.

12.3 Pharmacokinetics

inistration of Everolimus tablets in patients with advanced solid tumors, peak everolimus concentrations are reached 1 to 2 hours after administration of oral doses ranging from 5 mg to 70 mg. Following single doses, C_{max} is dose-proportional with daily dosing between 5 mg and 10 mg. With single doses of 20 mg and higher, the increase in C_{max} is less than dose-proportional; however AUC shows dose-proportionality over the 5 mg to 70 mg dose range. Steady-state was achieved within 2 weeks following once-daily dosing. In patients with TSC-associated SEGA, everolimus C_{min} was approximately dose-proportional within the dose

Effect of Food: In healthy subjects, a high-fat meal (containing approximately 1000 calories and 55 grams of fat) reduced systemic exposure to Everolimus Tablets 10 mg (as measured by AUC) by 22% and the peak blood concentration C_{\max} by 54%. Light-fat meals (containing approximately 500 calories and 20 grams of fat) reduced AUC by 32% and C_{\max} by 42%. The blood-to-plasma ratio of everolimus, which is concentration-dependent over the range of 5 to 5000 ng/mL, is 17% to 73%. The amount of everolimus confined to the plasma is approximately 20% at blood concentrations observed in cancer patients given Everolimus Tablets 10 mg orally once daily. Plasma protein binding is approximately 74% both in healthy subjects and in patients with moderate hepatic impairment.

he mean elimination half-life of everolimus is approximately 30 hours.

ing component in human blood. Six main metabolites of everolimus have been detected in human blood, including three monohydroxylated metabolites, two hydrolytic ring-opened products, and a phosphatidylcholine conjugate of everolimus. These metabolites were also identified in animal species used in toxicity studies, and showed approximately 100-times less activity than everolimus itself. Excretion: No specific elimination studies have been undertaken in cancer patients. Following the administration of a 3 mg single dose of radiolabeled everolimus in patients who were receiving cyclosporine, 80% of the adioactivity was recovered from the feces, while 5% was excreted in the urine. The parent substance was not

detected in urine or feces. $\underline{Specific\ Populations}$ No relationship was apparent between oral clearance and age or sex in patients with cancer.

Patients with Renal Impairment: No significant influence of creatinine clearance (25 to 178 mL/min) was detected on oral clearance (CL/F) of everolimus. Patients with Hepatic Impairment: Compared to normal subjects, there was a 1.8-fold, 3.2-fold, and 3.6-fold increase in AUC for subjects with mild (Child-Pugh class A), moderate (Child-Pugh class B), and severe (Child-Pugh class C) hepatic impairment, respectively. In another study, the average AUC of everolimus in subjects with moderate hepatic impairment (Child-Pugh class B) was twice that found in subjects with normal hepatic function [see Dosage and Administration (2.10), Use in Specific Populations (8.6)].

Pediatric Patients: In patients with TSC-associated SEGA, the mean C_{min} values normalized to mg/m² dose in pediatric patients (< 18 years of age) were lower than those observed in adults, suggesting that everolimus clearance adjusted to BSA was higher in pediatric patients as compared to adults. Race or Ethnicity: Based on a cross-study comparison. Japanese patients had on average exposures that were higher than non-Japanese patients receiving the same dose. Oral clearance (CLIF) is on average 20% higher in Black patients than in White patients.

<u>Drug Interaction Studies</u>
<u>Effect of CYP3A4 and P-glycoprotein (P-gp) Inhibitors on Everolimus:</u> Everolimus exposure increased when /erolimus was coadministered with:
• ketoconazole (a P-gp and strong CYP3A4 inhibitor) - C_{max} and AUC increased by 3.9- and 15-fold, respectively. \bullet erythromycin (a P-gp and moderate CYP3A4 inhibitor) - C_{max} and AUC increased by 2- and 4.4-fold, respectively. verapamil (a P-gp and moderate CYP3A4 inhibitor) - C_{max} and AUC increased by 2.3- and 3.5-fold,

Effect of CYP3A4 and P-gp Inducers on Everolimus: The coadministration of Everolimus with rifampin, a P-gp and strong inducer of CYP3A4, decreased everolimus AUC by 63% and C_{max} by 58% compared to Everolimus alone [see Dosage and Administration (2.12)]. Effect of Everolimus on CYP3A4 Substrates: No clinically significant pharmacokinetic interactions were observed between Everolimus and the HMG-CoA reductase inhibitors atorvastatin (a CYP3A4 substrate), pravastatin (a non-CYP3A4 substrate), and simvastatin (a CYP3A4 substrate).

The coadministration of an oral dose of midazolam (sensitive CYP3A4 substrate) with Everolimus resulted in a 25% increase in midazolam C_{max} and a 30% increase in midazolam AUC $_{\text{0-art}}$ The coadministration of Everolimus with exemestane increased exemestane $C_{\rm SR}$ by 45% and $C_{\rm 2h}$ by 64%; however, the corresponding estradiol levels at steady state (4 weeks) were not different between the 2 treatment arms. No increase in adverse reactions related to exemestane was observed in patients with hormone receptorpositive, HER2-negative advanced breast cancer receiving the combination.

The coadministration of Everolimus with long-acting octreotide increased octreotide C_{min} by approximately 50%. Effect of Everolimus on Antiepileptic drugs (AEDs): Everolimus increased pre-dose concentrations of the car-bamazepine, clobazam, oxcarbazepine, and clobazam's metabolite N-desmethylclobazam by about 10%. Everolimus had no impact on pre-dose concentrations of AEDs that are substrates of CYP3A4 (e.g., clonazepam and zonisamide) or other AEDs, including valproic acid, topiramate, phenobarbital, and phenytoin. 13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
Administration of everolimus for up to 2 years did not indicate oncogenic potential in mice and rats up to the
highest dosse tested (0.9 mg/kg) corresponding respectively to 3.9 and 0.2 times the estimated human exposure
based on AUC at the recommended dose of Everolimus 10 mg orally once daily. Everolimus was not genotoxic in a battery of in vitro assays (Ames mutation test in Salmonella, mutation test in Legislation was true genroused in a usuary or in virul assays (Anties insulation test in Salintorliaid, insulation test in 15.1788 mouse lymphoma cells, and chromosome aberration assay in V79 Chinese hamster cells). Everolimus was not genotoxic in an in vivo mouse bone marrow micronucleus test at doses up to 500 mg/kg/day (15.00 mg/m²/day, approximately 2.255-fold the recommended dose of Everolimus 10 mg orally once daily, and approximately 2.00-fold the median dose administered to patients with TSC-associated SEGA, based on the BSA), administered as 3.45 med 3.45 mg or 2.45 m

Pregnancy Testing 2 doses, 24 hours apart.

Verify the pregnancy status of females of reproductive potential prior to starting Everolimus Tablets (see Use in Specific Populations (8.1)].

Specific Populations (8.1)].

2 doses, 24 hours apart.

Based on non-clinical findings, Everolimus Tablets may impair male fertility. In a 13-week male fertility study in rats, testicular morphology was affected at doses of 0.5 mg/kg and above. Sperm motility, sperm count, and plasbased on non-clinical inlorings, experioritinal labels may impair male fertility. In a 13-week male fertility study rats, testicular morphology was affected at doses of 0.5 mg/kg and above. Sperm motility, sperm count, and plasma testosterone levels were diminished in rats treated with 5 mg/kg. The exposures at these doses (52 ng·hr/mL and 414 ng·hr/mL, respectively) were within the range of human exposure at the recommended dose of Everolimus 10 mg orally once daily (560 ng·hr/mL) and resulted in infertility in the rats at 5 mg/kg. Effects on male fertility occurred at AUC_{0.24h} values 10% to 81% lower than human exposure at the recommended dose of Everolimus 10 mg orally once daily. After a 10 to 13 week non-treatment period, the fertility index increased from Oral doses of everolimus in female rats at doses ≥ 0.1 mg/kg (approximately 4% the human exposure based on AUC at the recommended dose of Everolimus 10 mg orally once daily) resulted in increased incidence of pre-implantation loss, suggesting that the drug may reduce female fertility.

Of the 118 patients enrolled, 79 were randomized to Everolimus and 39 to placebo. The median age was 31 years 13.2 Animal Toxicology and/or Pharmacology
In juvenile rat toxicity studies, dose-related delayed attainment of developmental landmarks including delayed eye-opening, delayed reproductive development in males and females and increased latency time during the learning and memory phases were observed at doses as low as 0.15 mg/kg/day.

14.1 Hormone Receptor-Positive, HER2-Negative Breast Cancer
A randomized, double-blind, multicenter study (BOLERO-2, NCT00863655) of Everolimus tablets in combination with exemestane versus placebo in combination with exemestane was conducted in 724 postmenopausal women with estrogen receptor-positive, HER2-negative advanced breast cancer with recurrence or progression ollowing prior therapy with letrozole or anastrozole. Randomization was stratified by documented sensitivity to prior hormonal therapy (yes versus no) and by the presence of visceral metastasis (yes versus no). Sen to prior hormonal therapy was defined as either (1) documented clinical benefit (complete response [CR], partia response [PR], stable disease ≥ 24 weeks) to at least one prior hormonal therapy in the advanced setting or (2 at least 24 months of adjuvant hormonal therapy prior to recurrence. Patients were permitted to have received 0 to 1 prior lines of chemotherapy for advanced disease. The major efficacy outcome measure was progression-free survival (PFS) evaluated by RECIST (Response Evaluation Criteria In Solid Tumors), based on

Patients were randomized 2:1 to Everolimus tablets 10 mg orally once daily in combination with exemestane 25 mg once daily (n = 485) or to placebo in combination with exemestane 25 mg orally once daily (n = 239). The two treatment groups were generally balanced with respect to baseline demographics and disease characteristics. Patients were not permitted to cross over to Everolimus tablets at the time of disease progression.

nyestigator (local radiology) assessment. Other outcome measures included overall survival (OS) and objective

The trial demonstrated a statistically significant improvement in PFS by investigator assessment (Table 20 and Figure 1). The results of the PFS analysis based on independent central radiological assessment were consistent with the investigator assessment. PFS results were also consistent across the subgroups of age, race, presence and extent of visceral metastases, and sensitivity to prior hormonal therapy. Skin lesion response rates were assessed by local investigators for 77 patients in the Everolimus arm and 37 patients in the placebo arm who presented with skin lesions at study entry. The skin lesion response rate was statistically significantly higher in the Everolimus arm (26% vs. 0, p = 0.0011); all skin lesion responses were partial responses, defined as visual improvement in 50% to 99% of all skin lesions durable for at least 8 weeks (Physician's Global Assessment of Clinical Condition).


ORR was higher in the Everolimus Tablets in combination with exemestane arm versus the placebo in combination with exemestane arm (Table 20). There were 3 complete responses (0.6%) and 58 partial responses (12%) in the Everolimus Tablets arm. There were no complete responses and 4 partial responses (1.7%) in the placebo in combination with exemestane arm. Patients randomized to placebo were permitted to receive Everolimus at the time of angiomyolipoma progression or after the time of the primary analysis. After the primary analysis, patients treated with Everolimus underwent additional follow-up CT or MRI scans to assess tumor status until discontinuation of treatment or completion of 4 years of follow-up after the last patient was randomized. A total of 112 patients (79 randomized to Everolimus and 33 randomized to Everolimus streatment was 3.9 years (0.5 months to 5.3 years) and the median duration of follow-up was 3.9 years (0.5 months to 5.3 years) and the median duration of follow-up was 3.9 years (0.9 months to 5.4 years). During the follow-up period after the primary analysis, 32 patients (in addition to the 33 patients identified at the time of the primary analysis) had an angiomyolipoma response based upon independent central radiology review. Among the 65 responders out of 112 patients, the median time to angiomyolipoma response was 2.9 months (2.6 to 33.8 months). Fourteen percent of the 112 patients treated with Everolimus had angiomyolipoma progression by the end of the follow-up period. No patient underwent a nephrectomy for angiomyolipoma progression and one patient underwent renal embolization while treated with Everolimus. After a median follow-up of 39.3 months, there was no statistically significant difference in OS between the

Table 20: Efficacy Results in Hormone-Receptor Positive, HER2-Negative Breast Cancer in

		LERO-2		
nalysis	Everolimus Tablets with Exemestane N = 485	Placebo with Exemestane N = 239	Hazard ratio	P-value
ledian progression-free	survival (months, 95%	CI)		
nvestigator radiological eview	7.8 (6.9, 8.5)	3.2 (2.8, 4.1)	0.45 ^a (0.38, 0.54)	<0.0001b
ndependent ladiological review	11.0 (9.7, 15.0)	4.1 (2.9, 5.6)	0.38a (0.3, 0.5)	<0.0001b
est overall response (%	%, 95% CI)			
Objective response rate	12.6% (9.8, 15.9)	1.7% (0.5, 4.2)	n/a ^d	
Hazard ratio is obtained	from the stratified Cox pro	portional-hazards mod	el by sensitivity to	prior hormon

ective response rate = proportion of patients with CR or PR Figure 1: Kaplan-Meier Curves for Progression-Free Survival by Investigator Radiological Review in Hormone Receptor-Positive, HER2-Negative Breast Cancer in BOLERO-2

p-value is obtained from the one-sided log-rank test stratified by sensitivity to prior hormonal therapy and




Pancreatic Neuroendocrine Tumors (PNET)
A randomized, double-blind, multi-center trial (RADIANT-3, NCT00510068) of Everolimus in combination with best supportive care (BSC) compared to placebo in combination with BSC was conducted in patients with locally stranged or metastatic advanced PNET and disease progression within the prior 12 months. Patients were atvanted by prior cytotoxic chemotherapy (yes versus no) and WHO performance status (0 versus 1 and 2). Treatment with somatostatin analogs was allowed as part of BSC. The major efficacy outcome was PFS evaluated by RECIST. After documented radiological progression, patients randomized to placebo could receive open-label Everolimus. Other outcome measures included ORR, response duration, and OS. Patients randomized to placebo were permitted to receive Everolimus at the time of SEGA progression or after

Patients were randomized 1:1 to receive either Everolimus 10 mg once daily (n = 207) or placebo (n = 203). Demographics were well balanced (median age 58 years, 55% male, 79% White). Of the 203 patients randomized to BSC, 172 patients (85%) received Everolimus following documented radiologic progression. The trial demonstrated a statistically significant improvement in PFS (Table 21 and Figure 2). PFS improvement in PFS (Table 21 and Figure 2). was observed across all patient subgroups, irrespective of prior somatostatin analog use. The PFS results by investigator radiological review, central radiological review and adjudicated radiological review are shown below

analysis	N	Everolimus Tablets N = 207	Placebo N = 203	Hazard Ratio (95% CI)	P-value
	410		ression-free nths) (95% CI)		
nvestigator radiological review		11.0 (8.4, 13.9)	4.6 (3.1, 5.4)	0.35 (0.27, 0.45)	<0.001
entral radiological review		13.7 (11.2, 18.8)	5.7 (5.4, 8.3)	0.38 (0.28, 0.51)	<0.001
djudicated radiological review ^a		11.4 (10.8, 14.8)	5.4 (4.3, 5.6)	0.34 (0.26, 0.44)	<0.001

Figure 2: Kaplan-Meier Curves for Progression-Free Survival by Investigator Radiological Review in PNET in RADIANT-3



nvestigator-determined response rate was 4.8% in the Everolimus arm and there were no complete responses. Overall Survival (OS) was not statistically significantly different between arms [HR = 0.94 (95% CI 0.73, 1.20);

Lack of Efficacy in Locally Advanced or Metastatic Functional Carcinoid Tumors

The safety and effectiveness of Everolimus Tablets in patients with locally advanced or metastatic functional carcinoid tumors have not been demonstrated. In a randomized (1:1), double-blind, multi-center trial (RADIANT-2, NCT00412061) in 429 patients with carcinoid tumors. Everolimus Tablets in combination with long-acting orderabide, Sandostatin LaBel" was compared to placebo in combination with song-acting orderabide, Sandostatin LaBel" was compared to placebo in combination with song-acting orderabide. Sandostatin LaBel" was compared to placebo in combination with song-acting orderabide. Sandostatin LaBel" was compared to placebo in combination with song-acting orderabide. long-acting octreotide (Sandostatin LAR®) was compared to placebo in combination with long-acting octreotide. After documented radiological progression, patients on the placebo arm could receive Everolimus Tablets; of those randomized to placebo, 67% received open-label Everolimus Tablets in combination with long-acting octreotide. The study did not meet its major efficacy outcome measure of a statistically significant improvement in PFS and the final analysis of OS favored the placebo in combination with long-acting octreotide arm.

14.3 Renal Cell Carcinoma (RCC)
An international, multi-center, randomized, double-blind trial (RECORD-1, NCT00410124) comparing Everolimus 10 mg once daily and placebo, both in conjunction with BSC, was conducted in patients with metastatic RCC whose disease had progressed despite prior treatment with sunitinib, sorafenib, or both sequentially. Prior therapy with bevacizumab, interleukin 2, or interferon-a was also permitted. Randomization was stratified according to prognostic score and prior anticancer therapy. The major efficacy outcome measure for the trial was PFS evaluated by RECIST, based on a blinded, independent, central radiologic review. After documented radiological progression, patients randomized to placebo could receive open-label Everolimus. Other outcome measures included OS.

In total, 416 patients were randomized 2:1 to receive Everolimus (n = 277) or placebo (n = 139). Demographics were well balanced between the arms (median age 61 years; 77% male, 88% White, 74% received prior sunitinib or sorafenib, and 26% received both sequentially). Everolimus was superior to placebo for PFS (Table 23 and Figure 4). The treatment effect was similar across prognostic scores and prior sorafenib and/or sunitinib. Final OS results yield a hazard ratio of 0.90 (95% Ct. 0.71, 1.14), with no statistically significant difference between the arms. Planned cross-over from placebo due to disease progression to open-label Everolimus occurred in 80% of the 139 patients and may have confounded

Table 23: Progression-Free Survival and Objective Response Rate by Central Radiologic Review in RCC in RECORD-1 (4.0, 5.5) (1.8, 1.9) (0.25, 0.43)

Figure 4: Kaplan-Meier Curves for Progression-Free Survival in RCC in RECORD-1 Logrank p value: <0.000

14.4 Tuberous Sclerosis Complex (TSC)-Associated Renal Angiomyolipoma
Arandomized (2:1), double-blind, placebo-controlled trial (EXIST-2, NCT00790400) of Everolimus was conducted in 118 patients with renal angiomyolipoma as a feature of TSC (n = 113) or sporadic lymphangioleiomyomatosis (n = 5). The key eligibility requirements for this trial were at least one angiomyolipoma of ≥ 3 cm in longest diameter on CT/MRI based on local radiology assessment, no immediate indication for surgery, and age ≥ 18 years. Patients received Everolimus 10 mg or matching placebo orally once daily until disease progression or unacceptable toxicity. CT or MRI scans for disease assessment were obtained at baseline, 12, 24, and 48 weeks and annually thereafter. Clinical and photographic assessment of skin lesions were conducted at baseline and every 12 weeks thereafter until treatment discontinuation. The major efficacy outcome measure was angiomyolipoma response rate based on independent central radiology review, which was defined as a ≥ 50% reduction in angiomyolipoma volume, absence of new angiomyolipoma lesion ≥ 1 cm, absence of kidney volume increase ≥ 20%, and no angiomyolipoma related bleeding of ≥ Grade 2. Key supportive efficacy outcome measures were time to angiomyolipoma progression and skin lesion response rate. The primary analyses of efficacy outcome measures were limited to the blinded treatment period and conducted 6 months after the last patient was randomized. The comparative angiomyolipoma response rate analysis was stratified by use of enzyme-inducing antiepileptic drugs comparative angiomyolipoma response rate analysis was stratified by use of enzyme-inducing antiepileptic drugs (EIAEDs) at randomization (yes versus no).

the primary analysis, whichever occurred first. After the primary analysis, patients treated with Everolimus Tablest underwent additional follow-up MRI scans to assess tumor status until discontinuation of treatment or completion of 4 years of follow-up after the last patient was randomized. A total of 111 patients (78 patients randomized to Everolimus and 33 patients randomized to placebo) received at least one dose of Everolimus Tablets. Median duration of Everolimus treatment and follow-up was 3.9 years (0.2 to 4.9 years). By four years after the last patient was enrolled, 58% of the 111 patients treated with Everolimus had a $\geq 50\%$ reduction in SEGA volume relative to baseline, including 27 patients identified at the time of the primary analysis and 37 patients with a SEGA response after the primary analysis. The median time to SEGA response 5,3 months (2.5 to 33.1 months). Twelve percent of the 111 patients treated with Everolimus had documented

disease progression by the end of the follow-up period and no patient required surgical intervention for SEGA during the study. Study 2485 (NCT00411619) was an open-label, single-arm trial conducted to evaluate the antitumor activity of Everolimus 3 mg/m²/orally once daily in patients with SEGA and TSC. Serial radiological evidence of SEGA growth was required for entry. Tumor assessments were performed every 6 months for 60 months after the last patient was enrolled or disease progression, whichever occurred earlier. The major efficacy outcome measure was the reduction in volume of the largest SEGA lesion with 6 months of treatment, as assessed via independent

120 cm³ (3 to 4520 cm³) in the Everolimus Tablets and placebo arms, respectively. Forty-six (39%) patients had prior renal embolization or nephrectomy. The median duration of follow-up was 8.3 months (0.7 to 24.8 months) at the time of the primary analysis.

The renal angiomyolipoma response rate was statistically significantly higher in Everolimus-treated patients (Table 24). The median response duration was 5.3+ months (2.3+ to 19.6+ months).

I here were 3 patients in the Everolimus arm and 8 patients in the placebo arm with documented angiomyolipoma progression by central radiologic review (defined as a ≥ 25% increase from nadir in the sum of angiomyolipoma target lesion volumes to a value greater than baseline, appearance of a new angiomyolipoma ≥ 1 cm in longest diameter, an increase in renal volume ≥ 20% from nadir for either kidney and to a value greater than baseline, or Grade ≥ 2 angiomyolipoma-related bleeding). The time to angiomyolipoma progression was statistically significantly longer in the Everolimus arm (HR 0.08 [95% CI: 0.02, 0.37]; p < 0.0001).

Table 24: Angiomyolipoma Response Rate in TSC-Associated Renal Angiomyolipoma in EXIST-2

Patients randomized to placebo were permitted to receive Everolimus at the time of angiomyolipoma progression

14.5 Tuberous Sclerosis Complex (TSC)-Associated Subependymal Giant Cell Astrocytoma (SEGA)

EXIST-1
A randomized (2:1), double-blind, placebo-controlled trial (EXIST-1, NCT00789828) of Everolimus was conducted in 117 pediatric and adult patients with SEGA and TSC. Eligible patients had at least one SEGA lesion ≥ 1 cm in longest diameter on MRI based on local radiology assessment and one or more of the following: serial radiological evidence of SEGA growth, a new SEGA lesion ≥ 1 cm in longest diameter, or new or worsening hydrocephalus. Patients randomized to the treatment arm received Everolimus at a starting dose of 4.5 mg/m² daily, with subsequent dose adjustments as needed to achieve and maintain everorimus brough concentrations of 5 to 15 ng/mL as tolerated. Everolimus or matched placebo continued until disease progression or unacceptable toxicity. MRI scans for disease assessment were obtained at baseline, 12, 24, and 48 weeks, and annually thereafter.

The main efficacy outcome measure was SEGA response rate based on independent central radiology review. SEGA response was defined as a $\geq 50\%$ reduction in the sum of SEGA volume relative to baseline, in the absence of unequivocal worsening of non-target SEGA lesions, a new SEGA lesion ≥ 1 cm, and new or worsening hydrocephalus. The primary analysis of SEGA response rate was limited to the blinded treatment period and conducted 6 months after the last patient was randomized. The analysis of SEGA response rate was stratified by use of enzyme-inducing antiepileptic drugs (EIAEDs) at randomization (yes vs. no).

use of enzyme-including antiepileptic drugs (EIAELBs) at randomization (yes Vs. no).

Of the 117 patients enrolled, 78 were randomized to Everolimus and 39 to placebo. The median age was 9.5 years (0.8 to 26 years); a total of 20 patients were < 3 years, 54 patients were 3 to < 12 years, 27 patients were 12 to < 18 years, and 16 patients were ≥ 18 years; 57% were male, and 93% were White. At baseline, 18% of patients were receiving EIAEDs. Based on central radiology review at baseline, 98% of patients had at least one SEGA lesion ≥ 1.0 cm in longest diameter, 79% had bilateral SEGAs, 43% had ≥ 2 target SEGA lesions, 26% had growth in or into the inferior surface of the ventricle, 9% had evidence of growth beyond the subependymal tissue adjacent to the ventricle, and 7% had radiographic evidence of hydrocephalus. The median values for the sum of all target SEGA lesions at baseline were 1.63 cm² (0.18 to 25.15 cm²) and 1.30 cm² (0.32 to 9.75 cm²) in the Everolimus and placebo arms respectively. Eight (7%) patients had prior SEGA-related surgery. The median duration of follow-up was 8.4 months (4.6 to 17.2 months) at the time of primary analysis.

The SEGA response, acta, was statistically significantly binder, in Everolimus tracted natients (Table 25), at

The SEGA response rate was statistically significantly higher in Everolimus-treated patients (**Table 25**). At the time of the primary analysis, all SEGA responses were ongoing and the median duration of response was 5.3 months (2.1 to 8.4 months).

With a median follow-up of 8.4 months, SEGA progression was detected in 15.4% of the 39 patients randomized to receive placebo and none of the 78 patients randomized to receive Everolimus. No patient in either treatment arm required surgical intervention.

Table 25: Subependymal Giant Cell Astrocytoma Response Rate in TSC-Associated SEGA in EXIST-1

Everolimus Tablets Placebo p-value N=79 N=39

There were 3 patients in the Everolimus arm and 8 patients in the placebo arm with documented and

giomyolipoma response rate² - % 41.8 0 95% CI (30.8, 53.4) (0.0, 9.0)

central radiology review. Progression was defined as an increase in volume of the largest SEGA lesion over baseline that was ≥ 25% over the nadir observed on study. A total of 28 patients received Everolimus for a median duration of 5.7 years (5 months to 6.9 years); 82% of the 28 patients remained on Everolimus for at least 5 years. The median age was 11 years (3 to 34 years), 61% At the primary analysis, 32% of the 28 patients (95% CI: 16%, 52%) had an objective response at 6 months, defined as at least a 50% decrease in volume of the largest SEGA lesion. At the completion of the study, the median duration of durable response was 12 months (3 months to 6.3 years).

By 60 months after the last patient was enrolled, 11% of the 28 patients had documented disease progression. No tient developed a new SEGA lesion while on Everolimus. Nine additional patients were identified as having a ≥50% volumetric reduction in their largest SEGA lesion between 1 to 4 years after initiating Everolimus including 3 patients who had surgical resection with subsequent regrowth prior to receiving Everolimus 15 REFERENCES

1. OSHA Hazardous Drugs. OSHA. http://www.osha.gov/SLTC/hazardousdrugs/index.html. 16 HOW SUPPLIED/STORAGE AND HANDLING **Everolimus Tablets** 2.5 mg tablets
White to slightly yellow, capsule shaped tablets with a beveled edge and no score, engraved with "P" on one side and "119" on the other side; available in: Blisters of 28 tablets NDC 49884-119-91

Per independent central radiology review

Each carton contains 4 blister cards of 7 tablets each te to slightly yellow, capsule shaped tablets with a beveled edge and no score, engraved with "P" on one side Blisters of 28 tablets NDC 49884-125-91 Each carton contains 4 blister cards of 7 tablets each

7.5 mg tablets
White to slightly yellow, capsule shaped tablets with a beveled edge and no score, engraved with "P" on one side and "127" on the other side; available in: Blisters of 28 tablets NDC 49884-127-91

and "128" on the other side: available in Blisters of 28 tablets NDC 49884-128-91

Store Everollimus Tablets at 25°C (77°F); excursions permitted between 15°C to 30°C (59°F to 86°F). See USP Controlled Room Temperature Store in the original container, protect from light and moisture Keep this and all drugs out of the reach of children.

Each carton contains 4 blister cards of 7 tablets each

Follow special handling and disposal procedures for anticancer pharmaceuticals. 17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling (Patient Information and Instructions for Use)

Non-infectious Pneumonitis
Advise patients of the risk of developing non-infectious pneumonitis and to immediately report any new or worsening respiratory symptoms to their healthcare provider [see Warnings and Precautions (5.1)]. Advise patients that they are more susceptible to infections and that they should immediately report any signs or symptoms of infections to their healthcare provider [see Warnings and Precautions (5.2)].

Hypersensitivity Reactions
Advise patients of the risk of clinically significant hypersensitivity reactions and to promptly contact their health-care provider or seek emergency care for signs of hypersensitivity reaction including rash, itching, hives, difficulty breathing or swallowing, flushing, chest pain, or dizziness [see Contraindications (4), Warnings and Precautions (5)] Angioedema with Concomitant Use of ACE Inhibitors
Advise patients to avoid ACE inhibitors and to promptly contact their healthcare provider or seek emergency care for signs or symptoms of angioedema [see Warnings and Precautions (5.4)].

Stomatitis

Advise patients of the risk of stomatitis and to use alcohol-free mouthwashes during treatment [see Warnings and Precautions (5.5)].

Risk of Impaired Wound Healing
Advise patients that Everolimus tablets may impair wound healing. Advise patients to inform their healthcare provider of any planned surgical procedure. [see Warnings and Precautions (5.7)].

Geriatric Patients
Inform patients that in a study conducted in patients with breast cancer, the incidence of deaths and adverse

reactions leading to permanent discontinuation was higher in patients ≥ 65 years compared to patients < 65 years [see Warnings and Precautions (5.8), Use in Specific Populations (8.5)]

dvise patients of the risk of developing kidney failure and the need to monitor their kidney function periodically

Metabolic Disorders
Advise patients of the risk of metabolic disorders and the need to monitor glucose and lipids periodically during therapy [see Warnings and Precautions (5.9)].

Risk of Infection or Reduced Immune Response with Vaccination
Advise patients to avoid the use of live vaccines and close contact with those who have received live vaccines [see Warnings and Precautions (5.11)]. Embryo-Fetal Toxicity
Advise females of reproductive potential of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment and for 8 weeks after the last dose. Advise patients to inform their healthcare provider of a known or suspected pregnancy. Advise males with female partners of reproductive potential to use effective contraception during treatment and for 4 weeks after the last dose [see Warnings and Precautions (5.13) and Use in Specific Populations (8.1, 8.3)].

dvise patients of the risk of myelosuppression and the need to monitor CBCs periodically during therapy [see

Radiation Sensitization and Radiation Recall
Radiation sensitization and recall can occur in patients treated with radiation prior to, during, or subsequent to
Everolimus Tablets treatment. Advise patients to inform their health care provider if they have had or are planning
to receive radiation therapy [see Warnings and Precautions (5.12]]. Lactation
Advise women not to breastfeed during treatment with Everolimus tablets and for 2 weeks after the last dose [see Use in Specific population (8.2)]

Infertility
Advise males and females of reproductive potential of the potential risk for impaired fertility [see Use in Specific Populations (8.3)] PATIENT INFORMATION Everolimus (E ver OH li mus) Tablets

What is the most important information I should know about Everolimus Tablets?

Everolimus Tablets can cause serious side effects, including:

1. You may develop lung or breathing problems. In some people lung or breathing problems may be severe and can lead to death. Tell your healthcare provider right away if you have any of these symptoms:

New or worsening cough
Shortness of breath
Chest pain

2. You may be more likely to develop an infection, such as pneumonia, or a bacterial, fungal or viral infection Viral infections may include active hepatitis B in people who have had hepatitis B in the past (reactivation). In some people (including adults and children) these infections may be severe and can lead to death. You may need to be treated as soon as possible Tell your healthcare provider right away if you have a temperature of 100.5°F or above, chills, or do not

Symptoms of hepatitis B or infection may include the following:

Chills
 Joint pain and swelling
 Loss of appetite
 Pale stools or dark urine
 Pain in the upper right side of the stomach

Severe allergic reactions. Call your healthcare provider or get medical help right away if you get signs and symptoms of a severe allergic reaction including: rash, itching, hives, flushing, trouble breathing or swallowing, chest pain or dizziness. Possible increased risk for a type of allergic reaction called angioedema, in people who take all Angiotensin-Converting Enzyme (AČE) inhibitor medicine during treatment with Everolimus Tablets. Talk with your healthcare provider before taking Everolimus Tablets if you are not sure if you take an ACE inhibitor medicine. Get medical help right away if you have trouble breathing or develop swelling of your tongue, mouth, or throat during treatment with Everolimus Tablets.

or unual during dearment with Everolimus lablets.

5. Mouth ulcers and sores. Mouth ulcers and sores are common during treatment with Everolimus Tablets but can also be severe. When you start treatment with Everolimus Tablets, your healthcare provider may tell you to also start a prescription mouthwash to reduce the likelihood of getting mouth ulcers or sores and to reduce their severity. Follow your healthcare provider's instructions on how to use this prescription mouthwash. If you develop pain, discomfort, or open sores in your mouth, tell your healthcare provider. Your healthcare provider may tell you to re-start this mouthwash or to use a special mouthwash or mouth gel that does not contain alcohol, peroxide, iodine or thyme.

6. You may develop kidney failure. In some people this may be severe and can lead to death. Your healthcare provider should do tests to check your kidney function before and during your treatment with If you have any of the serious side effects listed above, you may need to stop taking Everolimus Tablets for a while

advanced hormone receptor-positive, HER2-negative breast cancer, along with the medicine exemestane, in postmenopausal women who have already received certain other medicines for their cancer.
adults with a type of pancreatic cancer known as pancreatic neuroendocrine tumor (PNET), that has progressed and cannot be treated with surgery. Everolimus Tablets are not for use in people with carcinoid tumors that actively produce hormones.

· adults with advanced kidney cancer (renal cell carcinoma or RCC) when certain other medicines have people with the following types of tumors that are seen with a genetic condition called tuberous sclerosis o adults with a kidney tumor called angiomyolipoma, when their kidney tumor does not require surgery

adults and children 1 year of age and older with a brain tumor called subependymal giant cell astrocy-

toma (SEGA) when the tumor cannot be removed completely by surgery t is not known if Everolimus Tablets are safe and effective in children to treat:

hormone receptor-positive, HER2-negative breast cancer
 kidney cancer (renal cell carcinoma)
 a kidney tumor called angiomyolipoma, that can happen in children with a genetic condition called tuberous sclerosis complex (TSC).

Do not take Everolimus Tablets if you have had a severe allergic reaction to everolimus. Talk to your healthcare provider before taking this medicine if you are allergic to: · a medicine that contains temsirolimus

Ask your healthcare provider if you do not know Before taking Everolimus Tablets, tell your healthcare provider about all of your medical conditions.

ncluding if you: Have or have had kidney problems Have or have had liver problem

Have diabetes or high blood sug Are scheduled to receive any vaccinations. You should not receive a "live vaccine" or be around people who have recently received a "live vaccine" during your treatment with Everolimus Tablets. If you are not sure about the type of immunization or vaccine, ask your healthcare provider. For children with TSC and SEGA or certain types of seizures, work with your healthcare provider to complete the recommended childhood series of vaccines before your child starts treatment with Everolimus Tablets.

· Are pregnant, can become pregnant, or have a partner who can become pregnant. Everolimus Tablets can remails who are able to become pregnant:

- Your healthcare provider will give you a pregnancy test before you start treatment with Everolimus Tablets.

- Your healthcare provider will give you a pregnancy test before you start treatment with Everolimus Tablets.

- You should use effective birth control during treatment and for 8 weeks after your last dose of Everolimus

Males with a female partner, you should use effective birth control during treatment and for 4 weeks after your Males with a temale partner, you should use ellective pirit contributed unling deathers and or a weeks after your last dose of Everolimus Tablets.

Talk to your healthcare provider about birth control methods that may be right for you during this time. If you become pregnant or think you are pregnant, tell your healthcare provider right away.

Are breastfeeding or plan to breastfeed, It is not known if Everolimus Tablets pass into your breast milk. Do not breastfeed during treatment and for 2 weeks after your last dose of Everolimus tablets. neasured uning treatment and on 2 weeks after your last dose of Everolimus tablets.

Are planning to have surgery, or if you have had a recent surgery, You should stop taking Everolimus Tablets at least 1 week before planned surgery. See "What are the possible side effects of Everolimus Tablets?" Have received radiation therapy or are planning to receive radiation therapy in the future. See "What are the possible side effects of Everolimus Tablets?"

Tell your healthcare provider about all of the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Everolimus Tablets may affect the way other medicines work, and other medicines can affect how Everolimus Tablets work. Taking Everolimus Tablets with other medicines can cause serious side effects. Know the medicines you take. Keep a list of them and show it to your healthcare provider and pharmacist when you get a new medicine. Especially tell your healthcare provider if you take • St. John's Wort (*Hypericum perforatum*)

Fungal infections Heart conditions or high blood pressure Medicines that weaken your immune system (your body's ability to fight infections and other problems) Ask your healthcare provider or pharmacist if you are not sure if your medicine is one of those taken for the

conditions listed above. If you are taking any medicines for the conditions listed above, your healthcare provider might need to prescribe a different medicine or your dose of Everolimus Tablets may need to be changed. You should also tell your healthcare provider before you start taking any new medicine. How should I take Everolimus Tablets?

Your healthcare provider will prescribe the dose of Everolimus Tablets that is right for you.

Take Everolimus Tablets exactly as your healthcare provider tells you to.

Your healthcare provider may change your dose of Everolimus Tablets or tell you to temporarily interrupt dosing, if peopled.

If needed.

Use scissors to open the blister pack.

*Iake Everolimus Tablets 1 time each day at about the same time.

*Take Everolimus Tablets the same way each time, either with food or without food.

*If you take too much Everolimus Tablets contact your healthcare provider or go to the nearest hospital emergency room right away. Take the pack of Everolimus Tablets with you.

*If you miss a dose of Everolimus Tablets, you may still take it if it is less than 6 hours after the time you normally take it. If it is more than 6 hours after you normally take your Everolimus Tablets, sky pith dose for that day. The part day take Sprolimus Tablets at you still time. Does the key done to make up for a prisend does, if you

take it. If it is more than 6 hours after you normally take your Everolimus Tablets, skip the dose for that day. The next day, take Everolimus Tablets at your usual time. Do not take 2 doses to make up for a missed dose. If you are not sure about what to do, call your healthcare provider.

*You should have blood tests before you start Everolimus Tablets and as needed during your treatment. These will include tests to check your blood cell count, kidney and liver function, cholesterol, and blood sugar levels.

*If you take Everolimus Tablets to treat SEGA, you will also need to have blood tests regularly to measure how much medicine is in your blood. This will help your healthcare provider decide how much Everolimus Tablets you need to take you need to lake.

Everolimus Tablets:

Swallow Everolimus Tablets whole with a glass of water. Do not take any tablet that is broken or crushed. What should I avoid while taking Everolimus Tablets?

You should not drink grapefurit juice or eat grapefurit during your treatment with Everolimus Tablets. It may make the amount of Everolimus Tablets in your blood increase to a harmful level. What are the possible side effects of Everolimus Tablets Everolimus Tablets can cause serious side effects, including:
• See "What is the most important information I should know about Everolimus Tablets?" for more Risk of wound healing problems. Wounds may not heal properly during Everolimus Tablets treatment. Tell

ats. You should stop taking Everolimus Tablets at least 1 week before planned surgery. Your healthcare nrovider should tell you when you may start taking Everolimus Tablets again after surgery. • You should stop taking Everoimus lablets at least 1 week before planned surgery.
• Your healthcare provider should tell you when you may start taking Everoimus Tablets again after surgery.
Increased blood sugar and fat (cholesterol and triglyceride) levels in the blood. Your healthcare provider should do blood tests to check your fasting blood sugar, cholesterol, and triglyceride levels in the blood before you start and during treatment with Everoimus Tablets.
Decreased blood cell counts. Everoimus Tablets can cause you to have decreased red blood cells, white blood cells, and platelets. Your healthcare provider should do blood tests to check your blood cell counts before you start and during treatment with Everoimus Tablets.

· Worsening side effects from radiation treatment, that can sometimes be severe. Tell your healthcare provider if you have had or are planning to receive radiation therapy. The most common side effects of Everolimus Tablets in people with advanced hormone receptor-positive, HER2-negative breast cancer, advanced neuroendocrine tumors of the pancreas, stomach and intestine (gastrointestinal) or lung, and advanced kidney cancer include:

Diarrhea
• Cough
Swelling of arms, hands, feet, ankles, face or other parts of the body The most common side effects of Everolimus Tablets in people who have SEGA, renal angiomyolipoma, or certain types of seizures with TSC include respiratory tract infections. Other side effects that may occur with Everolimus Tablets: rolimus tablets may affect fertility in females and may affect your ability to become pregnant. Talk to your

Everolimus tablets may affect fertility in males and may affect your ability to father a child. Talk to your healthcare provider if this is a concern for you. Tell your healthcare provider if you have any side effect that bothers you or does not go away. These are not all the possible side effects of Everolimus Tablets. For more information, ask your healthcare

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. How should I store Everolimus Tablets?

• Store Everolimus Tablets at room temperature, between 68°F to 77°F (20°C to 25°C).

• Keep Everolimus Tablets in the pack it comes in. Open the blister pack just before taking Everolimus Tablets.

Keep Everolimus Tablets dry and away from light.
Do not use Everolimus Tablets that is out of date or no longer needed Keep Everolimus Tablets and all medicines out of the reach of children General information about the safe and effective use of Everolimus Tablets Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use Everolimus Tablets for a condition for which it was not prescribed. Do not give Everolimus Tablets to other processing the proces

For more information call 1-800-828-9393 or go to www.parpharm.com. What are the ingredients in Everolimus Tablets?

people, even if they have the same problem you have. It may harm them.

Feeling weak or tired

Inactive ingredients: hypromellose, butylated hydroxytoluene, lactose anhydrous, crospovidone, colloidal silicon dioxide and magnesium stearate. This Patient Information has been approved by the U.S. Food and Drug Administration.

OS119-01-1-03

(18 to 61 years), 34% were male, and 89% were White. At baseline, 17% of patients were receiving EIAEDs. On central radiology review at baseline, 92% of patients had at least 1 angiomyolipoma of ≥ 3 cm in longest diameter. 29% had angiomyolipomas ≥ 8 cm, 78% had bilateral angiomyolipomas, and 97% had skin lesions. The median Read this Patient Information leaflet that comes with Everolimus Tablets before you start taking it and each time you get a refill. There may be new information. This information does not take the place of talking to your health care provider about your medical condition or treatment. values for the sum of all target renal angiomyolipoma lesions at baseline were 85 cm³ (9 to 1612 cm³) and